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Resumo  
A tumorigénese é um processo complexo cujas várias fases reflectem alterações genéticas 
que resultam na transformação progressiva de células normais em células malignas (Hanahan 
& Weinberg, 2000; Renan, 1993). As principais características que ditam colectivamente o 
cancro são: auto-suficiência em relação aos sinais de crescimento, insensibilidade aos sinais de 
anti-crescimento, evasão à apoptose, elevado potencial replicativo, angiogénese sustentada, 
evasão ao controlo imunitário, reprogramação metabólica, invasão tecidular e metastização, 
representando esta última a principal causa de morbidez e morte associadas à doença 
(Hanahan & Weinberg, 2011). 
Todos estes atributos resultam de uma interacção dinâmica entre as células tumorais e o seu 
microambiente – microambiente tumoral –, que inclui células normais, factores mediadores e 
componentes da matriz extracelular (MEC) (Tlsty & Coussens, 2006). 
A fibronectina (FN) é uma glicoproteína modular de elevado peso molecular que pode ser 
classificada, de acordo com a sua solubilidade, em FN plasmática, solúvel, e FN celular, uma 
forma menos solúvel que representa o maior componente da MEC (Klein et al, 2004; Pankov & 
Yamada, 2002). Estruturalmente, a FN apresenta-se sob a forma de um dímero composto por 
duas cadeias polipeptídicas aproximadamente idênticas, ligadas covalentemente por um par 
de pontes dissulfito próximo da extremidade C-terminal. Cada monómero tem um peso 
molecular de 230-250 kDa e é composto por três tipos de unidades de repetição ou módulos: o 
tipo I (FI), o tipo II (FII) e o tipo III (FIII) (Hynes & Yamada, 1982; Pankov & Yamada, 2002; Potts 
& Campbell, 1996). 
A FN, que tem como receptores integrinas, está implicada numa grande variedade de 
funções celulares, sobretudo envolvendo interacções entre as células e a MEC, onde assume 
grande importância na adesão, morfologia, migração, crescimento e diferenciação celulares, 
organização do citosqueleto e hemostasia (Hynes & Yamada, 1982; Kornblihtt et al, 1996; 
Labat-Robert, 2002). 
As interacções célula-célula e célula-matriz são essenciais para o fornecimento de 
informações que regulam o normal funcionamento celular, pelo que a degradação ou 
activação das proteínas de matriz e/ou da superfície celular podem mediar alterações 
irreversíveis no microambiente celular (Werb, 1997). O crescimento tumoral, angiogénese, 
invasão e metastização estão fortemente dependentes da natureza permissiva do 
microambiente. Durante estas fases, a proteólise da MEC representa um passo crucial 
(Chambers & Matrisian, 1997; Polette et al, 2004), sendo reconhecida à FN uma forte 
susceptibilidade neste âmbito (Kenny et al, 2008). As metaloproteases de matriz (MPMs) 
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constituem a família de proteases mais importante associada à tumorigénese (Kessenbrock et 
al, 2010). As MPM-9 e MPM-2 têm sido apontadas como as MPMs mais importantes na 
metastização (Coussens et al, 2002; Klein et al, 2004; Malemud, 2006; Stetler-Stevenson, 
1999). 
O aumento concomitante de FN e enzimas proteolíticas, bem como de fragmentos de 
fibronectina tem sido observado em doentes de cancro (Katayama et al, 1993; Kenny et al, 
2008; Kenny & Lengyel, 2009; Labat-Robert, 2002; Labat-Robert et al, 1980; Warawdekar et al, 
2006), sugerindo uma possível intervenção da FN e seus fragmentos no processo tumoral, 
embora o eventual mecanismo subjacente ao fenómeno não seja ainda claro. Paralelamente, 
outros estudos têm atribuído propriedades anti-tumorais a alguns fragmentos derivados da FN 
(Humphries et al, 1986; Humphries et al, 1988; Kato et al, 2002; Saiki, 1997; Yi & Ruoslahti, 
2001). 
Com base no trabalho científico que vem sendo dedicado a esta temática, foi estabelecido 
como objectivo deste trabalho o estudo do papel da FN no desenvolvimento e progressão 
tumorais. Com este intuito, foi desenvolvido um trabalho experimental que partiu do 
estabelecimento de dois grupos, para diferentes linhas celulares, diferindo entre si nos níveis 
de FN produzida. Para isso, procedeu-se à construção de um plasmídeo contendo o gene da FN 
embrionária (full-length), pcDNA3-flFN. Este vector foi transfectado em células das linhas 
celulares tumorais humanas HCT15 (carcinoma colorrectal) e HeLa (adenocarcinoma do colo 
do útero), e da linha celular não-tumoral CHO, uma linha celular transformada onde o 
mecanismo de controlo de transcrição se encontra inactivado, tendo sido, por isso, utilizada 
como controlo positivo, in vitro. Para cada linha celular foi mantido um grupo de células 
controlo, não transfectadas. O trabalho experimental consistiu no desenvolvimento de ensaios 
in vitro e in vivo, após a indução da formação de tumores xenógrafos em modelos ortotópicos 
de ratinhos BALB/c-SCID. Os resultados foram comparados entre grupos. 
Após transfecção estável das linhas celulares, a expressão de FN foi determinada, para cada 
grupo, por PCR quantitativo em tempo-real. A detecção de níveis mais elevados de mRNA nos 
grupos controlo, para todas as linhas celulares – sobretudo em HCT15 e CHO –, validou o 
sucesso da transfecção, o que permitiu a progressão do trabalho experimental. Análises de 
western blotting – foram utilizadas como amostras a FN imunoprecipitada a partir do meio de 
cultura das células – e imunofluorescência confirmaram a existência de uma correlação entre 
níveis de mRNA e proteína, evidenciando valores proteicos de FN aumentados nos grupos 
transfectados, em comparação com os grupos controlo. 
Os resultados obtidos por western blotting mostraram, adicionalmente, a presença de 
fragmentos proteolíticos de FN nas linhas tumorais, não observada no controlo positivo (FN 
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imunoprecipitada a partir de soro de um individuo saudável), o que está de acordo com as 
observações de vários estudos realizados em doentes de cancro (Katayama et al, 1993; Kenny 
et al, 2008; Kenny & Lengyel, 2009; Labat-Robert, 2002; Labat-Robert et al, 1980; Warawdekar 
et al, 2006). Para as linhas celulares CHO e HCT15, foram detectados níveis mais elevados de 
fragmentos proteolíticos de FN nos grupos transfectados, o que está de acordo com o 
esperado, dada a maior concentração de FN nestes grupos. 
Por imunofluorescência, foi observada, globalmente, uma maior expressão de integrinas nas 
células transfectadas, resultado esperado sendo essas os receptores da FN. 
Por zimografia, foi avaliada a actividade das MPMs. Foi detectada actividade proteolítica das 
MPM-9 e MPM-2, consideradas as MPMs mais importantes no processo de metastização 
(Coussens et al, 2002; Klein et al, 2004; Malemud, 2006; Stetler-Stevenson, 1999). Para a 
MPM-9 foi observada uma actividade proteolítica aumentada nos grupos transfectados de 
HCT15 e CHO, assim como para a MPM-2 em HCT15. Estes resultados podem estar 
relacionados com a maior concentração de FN nos meios de cultura das células transfectadas e 
revelaram-se também consistentes com o padrão de fragmentos de FN obtido por western 
blotting. 
O estudo da migração celular foi abordado por wound healing assay, do qual resultaram 
taxas de migração direccional mais elevadas para as células CHO e HCT15 transfectadas, facto 
que poderá estar relacionado com os resultados obtidos na zimografia. 
Um eventual envolvimento da FN na angiogénese foi avaliado por tube formation assay com 
HUVEC (células endoteliais de cordão umbilical humano) e pela quantificação da expressão, a 
nível de mRNA, de três isoformas de VEGF (factor de crescimento do endotélio vascular), 
receptores do VEGF e angiopoietinas. Os resultados mostraram uma relação inversa entre os 
níveis de FN e a formação de tubos. 
Colectivamente, os resultados in vitro sugeriram uma correlação entre níveis mais elevados 
de FN e um comportamento mais agressivo por parte das células, num contexto neoplásico, 
sugerindo um particular envolvimento da migração das células tumorais. 
Após aproximadamente dois meses da indução da formação de tumores nos modelos 
BALB/c-SCID, os animais foram sacrificados e procedeu-se à colheita dos principais órgão-alvo 
de metastização. A análise histológica dos tumores e órgãos recolhidos revelou mais invasão e 
metastização nos grupos inoculados com células controlo. Estas observações foram 
confirmadas para o grupo inoculado com HCT15, pela detecção de mais mastócitos nos 
tumores, os quais estão implicados no crescimento tumoral e invasão (Strouch et al, 2010), e 
pela quantificação da expressão de SCF (factor de células estaminais) – citocina envolvida na 
promoção da sobrevivência, proliferação e migração de mastócitos e células progenitoras 
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(Broudy, 1997) – e SDF-1 (factor derivado do estroma da medula óssea) – citocina associada ao 
crescimento tumoral, angiogénese, metastização e recrutamento de células derivadas da 
medula óssea (Kryczek et al, 2007) –, que se revelou menor nas células transfectadas. 
Os resultados in vivo evidenciam, deste modo, um processo tumorigénico menos avançado 
nos animais inoculados com células transfectadas, contrariando as observações in vitro. Com 
efeito, uma taxa migratória mais elevada não implica necessariamente uma maior actividade 
invasiva por parte das céluals tumorais, a principal responsável pela disseminação do cancro. 
Por outro lado, as condições in vitro não incluem muitas variáveis existentes in vivo. 
Recomenda-se, no entanto, a validação dos modelos in vivo sob condições técnicas mais 
apropriadas. Não obstante, parece relevante a sequenciação de um fragmento detectado, para 
posterior investigação.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: cancro, metastização, microambiente tumoral, fibronectina (FN), 
fragmentos de fibronectina.
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Abstract 
Reciprocal interactions among normal cells, their mediators, components of the extracellular 
matrix (ECM) and genetically altered cells regulate all aspects of tumorigenicity. Fibronectin 
(FN), a multidomain glycoprotein, represents the major component of ECM and is implicated in 
a variety of cell functions, particularly those involving interactions between cells and ECM. 
ECM proteolysis is a crucial step during cancer stages and FN strong susceptibility to 
proteolytic degradation is well documented. Indeed, several studies have related FN levels to 
tumor progression in cancer patients, observing an increase of both FN and FN fragments 
levels. In parallel, some research has, on the other hand, provided evidence of protective roles 
of fragments derived from FN.  
Based on the literature that has been dedicated to the subject, it was established as 
objective of this work the study of the role of FN in tumor development and progression. For 
this purpose, an experimental work was developed arising from the establishment of two 
groups within each cell line used – tumor cell lines HCT15 and HeLa, and CHO –, differing in the 
levels of FN produced. In vitro and in vivo assays were performed and the results compared 
between groups. 
Our findings suggested a correlation between higher FN levels and a more aggressive 
behavior of cells in a neoplastic context, in vitro. In vivo, the opposite was observed. It is 
recommended, however, the validation of the in vivo models under improved technical 
conditions. Nevertheless, the sequence of a fragment detected appeared to be relevant for 
further investigation. 
 
 
 
 
 
 
 
 
 
Keywords: cancer, metastasis, tumor microenvironment, fibronectina (FN), fibronectin 
fragments.
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1. Introduction  
1.1    Cancer biology 
Tumorigenesis is a multistep process. Its stages reflect genetic alterations that drive the 
progressive transformation of normal human cells into highly malignant derivatives (Hanahan 
& Weinberg, 2000; Renan, 1993). The vast catalog of cancer types  is defined as having several 
properties, also termed “hallmarks”, that collectively define cancer: self-sufficiency in growth 
signals, insensitivity to antigrowth signals, evasion of programmed cells death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis 
(Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011).  
Evading immune system and reprogramming of metabolism are also two emerging hallmarks 
of cancer (Hanahan & Weinberg, 2011). In fact, with regard to evading immune system, solid 
tumors seem to avoid detection or limit the extent of the immune system action, responsible 
for recognizing and eliminating the majority of incipient cancer cells (Hanahan & Weinberg, 
2011). Other evidences have revealed that cancer cells are able to reprogram their glucose 
metabolism, and thus their energy production, by limiting their energy metabolism largely to 
glycolysis, even under aerobic conditions (DeBerardinis et al, 2008; Hanahan & Weinberg, 
2011). Although this metabolic switch represents a disadvantage in metabolic terms, increased 
glycolysis allows the diversion of glycolytic intermediates into various biosynthetic pathways, 
including those generating nucleosides and amino acids, facilitating the biosynthesis of the 
macromolecules and organelles required for assembly of new cells (Hanahan & Weinberg, 
2011; Vander Heiden et al, 2009). 
All these attributes of cancer result from a dynamical interaction between tumor cells and its 
microenvironment.  
In fact, for a long time only the neoplastic cells were the focus of interest in cancer research; 
the stroma was rather considered a reactive component without major significance (Wernert, 
1997). Research on the underlying mechanisms of cancer has, however, changed the level of 
importance ascribed to the tumor stroma (Kessenbrock et al, 2010; Tlsty & Coussens, 2006; 
Werb, 1997; Wernert, 1997). This is now considered to be an integral part of a neoplasm, 
perceived then as a complex tissue composed of multiple distinct cell types that participate in 
heterotypic interactions, creating the concept of tumor microenvironment (reviewed in 
(Hanahan & Weinberg, 2011).  
Besides the paracrine mode of action of growth factors that dominates physiological 
processes, in which cells require exogenous mitogenic growth signals to proliferate, many 
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tumor cells acquire the ability to generate growth factors to which they are responsive – 
autocrine stimulation (Sporn & Todaro, 1980; Witsch et al, 2010). Along with such autocrine 
loops, other mechanisms may also lead to constitutive pathway activation in tumors; at the 
receptor level, overexpression may enable cancer cells to become hyper-responsive to growth 
factors (for example, epidermal growth factor receptor (EGFR) in head and neck cancer), 
whereas specific mutations can elicit ligand-independent signaling (for example, brain tumor 
mutants of EGFR) (Di Fiore et al, 1987; Hanahan & Weinberg, 2000; Huang et al, 1997; Witsch 
et al, 2010); also the switch of the types of extracellular matrix (ECM) receptors cancer cells 
express, favoring ones that transmit progrowth signals, contributes to tumor self-sufficiency in 
growth signals (Lukashev & Werb, 1998). 
Loss of sensitivity to anti-growth signals complements the first hallmark of cancer by leading 
also to unchecked growth (Hanahan & Weinberg, 2000). Cell cycle involves multiple 
checkpoints that assess extracellular growth signals, cell size and DNA integrity, in which cyclin-
dependent kinases (CDKs) and cyclins act by inducing cell cycle progression, and CDKs 
inhibitors (CKIs) act as negative regulators (Park & Lee, 2003). Deregulation of the cell cycle is 
one of the most frequent alterations during tumor development (Evan & Vousden, 2001; Park 
& Lee, 2003).  
Cancer cells must also evade antiproliferative signals by turning off expression of integrins 
and other cell adhesion molecules that send antigrowth signals, favoring instead those that 
convey progrowth signals, and by avoiding terminal differentiation, for which mutations in the 
various proliferative control pathways can contribute additionally (Hanahan & Weinberg, 
2000).  
The ability of tumor cell populations to expand in number is also determined by the 
resistance to apoptosis. The most common strategy to avoid apoptosis is a mutation involving 
the p53 tumor suppressor, resulting in the removal of a key component of the DNA damage 
sensor that can induce the apoptotic effector cascade (Hanahan & Weinberg, 2000; Harris, 
1996; Levine, 1997). 
The loss of capacity for senescence leads tumor cells to limitless replicative potential 
(immortality), an essential feature for malignant growth state, achieved by telemore 
maintenance, which, in turn, results, in most cases, from the upregulating expression of 
telomerase, an enzyme that adds hexanucleotide repeats onto the ends of telomeric DNA, 
maintaining the telomeres at a length above a critical threshold, permitting unlimited 
multiplication of descendant cells (Bryan et al, 1995; Hanahan & Weinberg, 2000; Hayflick, 
1997). 
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Tumor cells initially lack angiogenic ability (Folkman, 1992; Hanahan & Weinberg, 2000). In 
order to expand in size, inicipient neoplasias must develop angiogenic ability, which seems to 
be acquired in a discrete step during tumor development, via an “angiogenic switch” (Hanahan 
& Folkman, 1996). That activation appears to occur by changing the balance of angiogenesis 
inducers and countervailing inhibitors (Hanahan & Folkman, 1996). This common shifting 
usually involves altered gene transcription. Many tumors show increased expression of 
vascular endothelial growth factor (VEGF) and/or fibroblast growth factors (FGFs), compared 
to normal tissues. The downregulation of endogenous inhibitors, such as thrombospondin-1 or 
β-interferon is also frequent (Hanahan & Weinberg, 2011; Singh et al, 1995). 
After the ability of tumor to grow beyond the limitations of passive nutrient diffusion, 
conferred by the acquisition of sustained angiogenesis, primary tumor masses release pioneer 
cells that invade adjacent tissues, and circulate, through bloodstream, to distant sites, where 
they may form new tumors, known as metastases (Kawaguchi, 2005; Sporn, 1996). 
 
1.2    Extracellular matrix and cancer 
Extracellular matrix (ECM) is a complex mixture of proteins and polysaccharides that are 
secreted locally and assembled into an organized network in close association with the surface 
of the cell that produced them (Alberts et al, 2002; Mosher et al, 1992; Pupa et al, 2002). Two 
main classes of extracellular macromolecules make up the matrix: polysaccharide chains of the 
class called glycosaminoglycans, which are usually found covalently linked to protein in the 
form of proteoglycans, and fibrous proteins, including collagen, elastin, fibronectin, and 
laminin, which have both structural and adhesive functions (Alberts et al, 2002).  
ECM provides structural and mechanical support to cells and tissues, and is also able to 
influence and interact with cells in the environment (Mosher et al, 1992; Pupa et al, 2002). The 
structural and regulatory molecules of the ECM function cooperatively to regulate a wide 
variety of cell processes such as growth, death, adhesion, migration, invasion, gene expression 
and differentiation (Assoian & Marcantonio, 1996; Pupa et al, 2002). These cell events, in turn, 
regulate physiological processes such as embryonic development, tissue morphogenesis and 
angiogenesis, and also, in certain circumstances, pathological processes (Assoian & 
Marcantonio, 1996; Mosher et al, 1992; Pupa et al, 2002). 
 
The tumor stroma contains a variety of macromolecules, most of which constitute the ECM: 
proteins, metalloproteins, glycoproteins, proteoglycans, proteases and their activators and 
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inhibitors, plus a variety of cells, including organ host specific cells, endothelial cells, pericytes, 
immune cells and fibroblasts (Desoize, 2004).  
Immune cells include granulocytes, dendritic cells, macrophages, natural killer cells, and 
mast cells, are components of premalignant and malignant tissues and contribute functionally 
to cancer development largely due to their release of soluble mediators that regulate cell 
proliferation, migration, blood vessels formation, tissue remodeling, metabolism, and genomic 
integrity (Bissell & Radisky, 2001; Tlsty, 2001; Tlsty & Coussens, 2006). Fibroblasts are primarily 
responsible for the synthesis, deposition, and remodeling of ECM, and for the production of 
many soluble paracrine growth factors that regulate cell proliferation, morphology, survival, 
and death (Allinen et al, 2004; Tlsty & Coussens, 2006). Blood vessels play a crucial role in 
maintaining tissue homeostasis and in metastasis (Ronnov-Jessen et al, 1996; Tlsty & 
Coussens, 2006).  
Reciprocal interactions among normal cells, their mediators, components of the ECM, and 
genetically altered neoplastic cells regulate all aspects of tumorigenicity. 
 
1.2.1    Fibronectin 
Fibronectin (FN) is a high molecular weight, multidomain glycoprotein (approximately 440 
kDa). A single gene codifies the FN protein core, but alternative splicing of its pre-mRNA leads 
to the expression of several isoforms (Kornblihtt et al, 1996; Pankov & Yamada, 2002). 
 Based on its solubility, FN can be subdivided into two forms: soluble plasma FN (pFN) and 
less-soluble cellular FN (cFN). Plasma FN is a major protein component of blood plasma (300 
μg/ml), being also present in other body fluids, it is synthesized mostly in the liver, by 
hepatocytes, and shows a relatively simple splicing pattern. Cellular FN is a key component of 
the extracellular matrix (ECM), secreted by several types of cells, primarily fibroblasts; it 
consists of a much larger and more heterogeneous group of FN isoforms resulting from cell 
type-specific and species-specific splicing patterns  (Hynes & Yamada, 1982; Klein et al, 2004; 
Pankov & Yamada, 2002; Tamkun & Hynes, 1983). 
FN exists, generally, as a dimer, composed of two nearly identical polypeptide chains 
covalently linked by a pair of C-terminal disulfide bonds. Each monomer has a molecular 
weight of 230–250 kDa and forms a mosaic protein filled almost entirely with three types of 
repeating units or modules: type I (FI), type II (FII) and type III (FIII) (figure 1) (Hynes & Yamada, 
1982; Pankov & Yamada, 2002; Potts & Campbell, 1996). FN contains 12 FI modules, 2 FII and 
15-17 FIII, accounting together for approximately 90% of the FN sequence (Pankov & Yamada, 
2002; Potts & Campbell, 1996). The carbohydrates constitute 4-9% of FN molecule, depending 
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on the cell source of the molecule. Their function on the molecule appears to be the 
stabilization of the molecule and the protection of specific regions against the proteolytic 
attack and abnormal turnover rates (Seppa et al, 1981).  
FI module contains approximately 45 amino acids with four cysteines forming two disulfide 
bonds. FII module is about 60 residues long and comprises two intrachain disulfide bonds. FIII 
module is about 90 amino acids in length and does not contain disulfide bonds. The three 
repeating units are also found in a wide range of vertebrate proteins, suggesting that FN 
evolved through exon shuffling (Hynes & Yamada, 1982; Kornblihtt et al, 1996; Patel et al, 
1987; Potts & Campbell, 1996).   
FN has been implicated in a wide variety of cell functions, particularly those involving 
interactions between cells and ECM. This glycoprotein plays important roles in cell adhesion, 
morphology and spreading, cytoskeletal organization, cell migration, growth and 
differentiation, phagocytosis, hemostasis and embryonic development in vertebrates (Hynes & 
Yamada, 1982; Kornblihtt et al, 1996; Labat-Robert, 2002). 
FN receptors are integrins – heterodimeric, transmembrane cell adhesion receptors, 
composed of two distinct glycoprotein chains, called the α (alpha) and β (beta) subunits, that 
mediate the attachment between ECM and cytoskeleton, playing also a role in cell signaling  
(Akiyama, 1996; Akiyama et al, 1995). Several integrins recognize FN: α5β1, α8β1, α3β1, αvβ1, 
αvβ3, αvβ6, αIIbβ3, and α4β1. Only α5β1 recognizes specifically FN, through its RGD (Arg-Gly-
Asp) sequence, located in the tenth FIII (FIII10) of the molecule; other integrins bind FN via the 
RGD sequence but bind also other ligands. Other sites recognized by α5β1 are located in FIII9 
and in an N-terminal fragment containing repeats FI1-9 and FII1-2 (figure 1) (Akiyama et al, 1995; 
Akiyama et al, 1989; Labat-Robert, 2002; Pankov & Yamada, 2002). 
Determination of integrin binding sites as well as of other important domains within the FN 
was greatly facilitated by the evidence that all FNs are cleaved only in specific regions when 
subjected to limited proteolytic digestion. FN binding activities are frequently preserved after 
such proteolysis (Akiyama et al, 1995; Hynes & Yamada, 1982; Pankov & Yamada, 2002). In 
fact, it has long been recognized that the functionality of FN is dissectable, and binding sites 
for a wide range of molecules have been associated with various fragments (Potts & Campbell, 
1996). 
 
Besides binding to cell surface through integrins, FN also interacts with several biologically 
important molecules, including heparin, collagen/gelatin and fibrin, and also some bacteria, 
being those interactions mediated by several distinct structural and functional domains (figure 
1). N-terminal domain has a central role in a number of important physiological processes: it 
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contains both covalent and a non-covalent fibrin binding sites, being the major site formed by 
FI4,5, and also binds to some bacteria; FI1-5, located in this domain, plays an important role in 
matrix assemby; heparin-binding sites are located also in the N-terminal end of the protein and 
in the C-terminal part (Hynes & Yamada, 1982; Mosher et al, 1991; Potts & Campbell, 1996). 
FIII modules also play a role in matrix assembly and heparin binding (Potts & Campbell, 1996). 
The collagen-binding domain include repeats FI6-9 and FII1,2 (Leikina et al, 2002; Pankov & 
Yamada, 2002). 
 
 
 
1.2.2    Extracellular matrix proteolysis: matrix metalloproteinases 
Cell-cell and cell-ECM interactions provide cells with information essential for controlling 
morphogenesis, cell fate specification, gain or loss of tissue-specific functions, cell migration, 
tissue repair, and cell death. Degradation or activation of cell surface and ECM proteins by 
proteolysis can mediate rapid and irreversible changes in the cellular microenvironment 
(Werb, 1997). 
Proteolysis plays an important role in regulating ECM formation and its structure 
remodeling, and in releasing of bioactive fragments and growth factors during growth, 
morphogenesis, and tissue repair. However, a deficient proteolytic activity, such as the 
excessive production of proteases, leads to the occurrence of pathological processes (Bugge et 
al, 1996). 
Figure 1 – Schematic representation of fibronectin and its main binding sites. 
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Malignant transformation deeply modifies the cell-cell and cell-ECM interactions. These 
alterations are globally defined as stromal reaction (Desoize, 2004; Labat-Robert, 2002; 
Wernert, 1997).   
Tumor growth, angiogenesis, invasion and metastasis are greatly dependent on the 
permissive nature of the microenvironment (Chambers & Matrisian, 1997; Polette et al, 2004). 
During these stages, ECM proteolysis represents a crucial step. Cancer cells and other cells 
belonging to the tumor stroma secrete, activate and/or induce high levels of proteolytic 
enzymes degrading ECM and cell-associated proteins.  The main enzymes that degrade ECM 
are tissue serine proteinases, including tissue plasminogen activator, urokinase, thrombin and 
plasmin, and the matrix metalloproteinases (MMPs) (Werb, 1997). Blocking the function of 
ECM proteases can decrease tumor growth, while their ectopic expression can increase 
carcinogenic potential, which suggests their contribution to the neoplastic process (Martin et 
al, 1996; Werb, 1997; Wilson et al, 1997). Some proteases, however, may inhibit tumorigenesis 
by inducing apoptosis or by releasing latent angiogenic inhibitors (Kaspar et al, 2006; Martin & 
Matrisian, 2007; Werb, 1997; Wilson et al, 1997). 
MMPs are a family of zinc-dependent endopeptidases produced by a number of cell types, 
capable of cleaving several macromolecules of the ECM, including FN (Giavazzi & Taraboletti, 
2001; Klein et al, 2004). MMPs are required for several normal physiological processes, 
including the skeletal and cardiovascular development, but also in diverse conditions and 
diseases, such as skeletal dysplasias, cardiovascular diseases, arthritis (Malemud, 2006). These 
enzymes represent also the most prominent family of proteases associated with 
tumorigenesis, where they play crucial functions in the molecular communication between 
tumor and stroma (Kessenbrock et al, 2010). MMP-2 and MMP-9 are thought to be the most 
important MMPs in metastasis (Coussens et al, 2002; Klein et al, 2004; Malemud, 2006; 
Stetler-Stevenson, 1999). 
Based on their structure and substrate specificity, MMPs are divided into five groups: 
collagenases, gelatinases, stomelysins, membrane-type MMPs and the others (MMPs not fully 
characterized). The substrates of collagenases substrates are mainly collagens; gelatinases 
mostly hydrolyze components of the basal lamina, gelatin and collagen type IV; and 
stromelysins mainly hydrolyze elastin and collagens types IV, V, XI and X; membrane-type 
MMPs are not grouped for their substrate specificity, but because they are all membrane 
bound (Klein et al, 2004; Vihinen & Kahari, 2002).  
During the neoplastic process, MMPs are produced mostly by tumor stroma cells and by 
tumor cells themselves (Page-McCaw et al, 2007). Their best known function is the 
degradation of ECM macromolecules, which permits to uncover or release cryptic sites of ECM 
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macromolecules that function to modulate a cellular response – matricryptic sites or matrikins 
– and which facilitates, thereby, the tumor cells migration and invasion (Polette et al, 2004). 
More recently, MMPs functions were, however, extended, being now recognized a more 
complex role in this context, although their role in the process of cancer is first attributed to 
their degradative capacity (Klein et al, 2004): MMPs also act as key regulators of various 
neoplastic processes, due to their abilities to mediate differentiation, proliferation and survival 
of tumor cells (Kenny et al, 2008; Lakka et al, 2003), to release growth factors from cell 
surfaces and reservoirs contained in the ECM, and to regulate tumor angiogenesis, mediating, 
therefore, great alterations in the microenvironment during tumor progression (Chantrain et 
al, 2004; Kenny et al, 2008).  In tumor angiogenesis, the main role for MMPs is degradation of 
ECM, which can result in migration of tumor cells as well as of endothelial cells, due to loss of 
cell-matrix contacts and cell-cell contacts, and release and/or activation of pro-angiogenic 
growth factors from ECM and/or inactive complexes, resulting in new vessel formation locally, 
although, almost simultaneously, negative regulators of angiogenesis, including MMP-
inhibiting fragments are formed through ECM degradation to control the local process of new 
vessel formation (Cao, 2001; Colorado et al, 2000; Klein et al, 2004; Nguyen et al, 2001). By 
regulating angiogenesis, MMPs become, consequently, important players in tumor growth and 
metastasis, for which these endopeptidases also contribute more directly enabling – again due 
to their degradative capacity – tumor cells to migrate and colonize host tissues (Klein et al, 
2004).  
 
1.3    Other intervenients in the tumorigenic process 
1.3.1    Growth factors and cancer progression 
Growth factors are compact polypeptides which bind to transmembrane receptors harboring  
kinase activity to stimulate specific combinations of intracellular signaling pathways, mediating 
the interplay between tumors and the ECM and non-cancer cells (Witsch et al, 2010).  
In the neoplastic context, growth factors assume a relevant role by representing the major 
regulators of all subsequent steps of tumor progression, after tumor initiation, instigated by 
oncogenic mutations, namely clonal expansion, invasion, angiogenesis and metastasis (Perona, 
2006; Witsch et al, 2010). 
The majority of growth factors receptors are single-pass transmembrane proteins harboring 
an intracellular tyrosine kinase domain (Perona, 2006; Witsch et al, 2010). Evidences have 
shown a critical involvement of tyrosine kinase receptors in the development and progression 
of human cancers (Zwick et al, 2001). Constitutive activation of tyrosine kinase receptors, 
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which has been shown to be important for malignant transformation and tumor proliferation, 
can occur by several mechanisms, being, in most cases, gene amplification, overexpression or 
mutations the main responsible for the acquired oncogenic potential of RTKs (Kolibaba & 
Druker, 1997; Zwick et al, 2001). 
Epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor-β 
(TGF-β), fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) are some 
of the relevant growth factor families in tumor progression (Perona, 2006; Witsch et al, 2010). 
Several FGFs have been identified as genes isolated from tumors due to their ability to 
induce proliferation or transformation of fibroblasts, which indicated a role in tumorigenesis 
(Kornmann et al, 1997; Zwick et al, 2001). Studies have demonstrated that alterations in the 
expression patterns of FGFs may contribute to growth deregulation of human tumor cells: 
expression of FGF-1 and FGF-2 in fibroblasts leads to transformation and tumor formation in 
nude mice; interferences with growth factor action have also resulted in impaired tumor 
growth (Auguste et al, 2001; Wang & Becker, 1997; Zwick et al, 2001). Changes at the level of 
FGFs receptors (tyrosine kinase receptors), have also been identified in a variety of human 
tumors: for instance, FGFR overexpression was observed in breast, prostate, melanoma, 
thyroid and salivary gland tumors (Giri et al, 1999; Shingu et al, 1998; Zwick et al, 2001); 
somatic mutations in FGFR-3 have been identified in bladder cancer and multiple myeloma 
(Cappellen et al, 1999; Chesi et al, 1997; Zwick et al, 2001). 
VEGF is one of the main inducers of endothelial cell proliferation and permeability of blood 
vessels, regulating, therefore, angiogenesis and vasculogenesis (Witsch et al, 2010; Zwick et al, 
2001).  This growth factors family consists of five glycoproteins, VEGFA (VEGF), VEGFB, VEGFC, 
VEGFD and PIGF (placenta growth factor), which bind at least to one of the three VEGF 
receptors, FLT-1 (VEGR-1), KDR (VEGFR-2, FLK-1) and FLT-4 (VEGFR-3). Several studies have 
provided evidence for the role of VEGF-VEGFR ligand-receptor system in tumor vascularization 
and metastasis (Padro et al, 2002; Trojan et al, 2004; Zwick et al, 2001). VEGF has been 
detected in different types of tumors.  Besides the proangiogenic effects, which confer to VEGF 
a pivotal role in maintaining the tumor growth by facilitating growth of new blood vessels 
(Perona, 2006), VEGF exerts independent of vascular processes, such as autocrine effects on 
tumor cell function (survival, migration, invasion), immune suppression and recruitment of 
bone marrow progenitors, which may dictate organ-specific tumor spread by homing to 
tumor-specific premetastatic sites and forming clusters that provide a permissive niche for 
incoming tumor cells (Kaplan et al, 2005; Santos & Dias, 2004; Serpa et al, 2010; Tammela et 
al, 2005). Expression of FLT-1 (VEGR-1) and KDR (VEGFR-2, FLK-1) has been detected on 
subsets of solid tumors and the activation of FLT-1 (VEGR-1) in breast cancer cells supports 
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their growth and survival (Witsch et al, 2010; Wu et al, 2006). Overexpression of VEGF and KDR 
(VEGFR-2, FLK-1) was also observed in the bone marrow of patients with acute myeloid 
leukemia (Padro et al, 2002). 
 
1.3.2    Tumor microenvironment: bone-marrow-derived cells 
Bone marrow (BM) contributes to the tumor microenvironment and recent studies have 
suggested that BM-derived microenvironments exert a direct impact in tumor pathophysiology 
(Gao & Mittal, 2009; Witsch et al, 2010). Growing tumors secrete growth factors into the 
peripheral circulation, causing the marrow microenvironment to acquire a highly pro-
angiogenic and protumorigenic environment, which promotes the mobilization of vascular, 
pericyte and hematopoietic progenitors, further recruited to the tumors, modifying the 
neoplastic properties of the malignant tumor cells (Gao & Mittal, 2009; Kopp et al, 2005).  
Of the BM-derived cells, much focus has been directed towards the pro-angiogenic 
hematopoietic cells, which exert their functions perivascularly through the paracrine release of 
pro-angiogenic cytokines (Gao & Mittal, 2009; Kopp et al, 2006; Lyden et al, 2001).  
Among the cells of the myeloid lineage, macrophages are prominent cells of the immune 
system that are recruited to tumors. Increased macrophage infiltration correlates with tumor 
stage and poor survival (Gao & Mittal, 2009; Torisu et al, 2000). BM-derived pericytes, vascular 
smooth muscle cells and mural cells stabilize nascent blood vessels by intimate perivascular 
association and contribute to neovascularization (Gao & Mittal, 2009; Song et al, 2005). BM-
derived mast cells have been implicated in tumor growth and invasion and associated with 
poor prognosis, being an abundant source of angiogenic factors, including VEGF and TGF-β, 
and MMP-9 (Theoharides & Conti, 2004). 
BM-derived endothelial progenitor cells (EPCs) contribute to neoangiogenesis by providing 
an alternative source of endothelial cells that contribute to neovessel formation, namely 
through paracrine secretion of proangiogenic growth factors as well as by direct luminal 
incorporation into sprouting nascent vessels (Lyden et al, 2001; Witsch et al, 2010). 
BM myeloid-derived suppressor cells (MDSCs) also contribute to tumor pathophysiology by 
participating in tumor immunity, inflammation and evasion or resistance to therapy. MDSCs, 
whose levels are often elevated in cancer patients, comprehend a heterogeneous group of 
cells that contribute to tumor escape, immune tolerance and suppression and also to TGF-β-
mediated metastasis (Gao & Mittal, 2009; Yang et al, 2008). These BM-derived cells have also 
been shown to provide resistance to immunotherapeutics by blocking immune responses 
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through suppression of antibody-producing B cells, CD4+ T cells and CD8+ T cells (Nagaraj et al, 
2007). 
 
1.4    Metastasis  
A major cause of morbidity and death due to cancer is the metastasis of cells from the 
primary tumor to distant sites where secondary tumors become established (Akiyama et al, 
1995).  
Primary tumors are originally incapable of invading the surrounding tissue. In the course of 
the disease the tumor mass becomes heterogeneous: primary tumor cells accumulate genetic 
alterations and interact with the local microenvironment (Scheel et al, 2007; Voulgari & 
Pintzas, 2009). As a result, some cells detach from neighboring ones, migrate and locally 
invade the surrounding tissue. Further access to the vascular or lymphatic systems leads to 
their dissemination in the body and finally to the re-establishment at distant sites. The first and 
determinant step of this process is the local invasion through the epithelial basement 
membrane, as it requires modifications in cell-cell and cell-matrix interactions, remodeling of 
the ECM, modifications of the cytoskeleton and enhancement of cell motility (Voulgari & 
Pintzas, 2009). However, not all types of cancer are capable of fulfilling these activities. This 
fact hypothesized that specific events induce a loss of epithelial and a gain of dedifferentiated 
mesenchymal-like phenotype – epithelial-mesenchymal transition (EMT) (Hugo et al, 2007; 
Voulgari & Pintzas, 2009). 
EMT, which represents a key step of embryogenesis, consists of the culmination of protein 
modification and transcriptional events in response to a defined set of extracellular stimuli 
leading to a cellular change (Hugo et al, 2007). Core elements of EMT include reduction of cell-
cell adherence via transcriptional repression and delocalization of cadherins (adherens 
junctions), occluding and claudin (tight junctions) and desmoplakin (desmosomes) (Hugo et al, 
2007; Klymkowsky, 2005). Circumferential F-actin fibres of the cytoskeleton are replaced by a 
network of stress fibers, at the tips of which ECM adhesion molecules localize. Matrix 
metalloproteinases (MMPs) are frequently upregulated, enabling cells to detach from each 
other (via E-cadherin cleavage) and to penetrate the basement membrane. These genetic 
alterations, along with changes in cell shape to a more elongated appearance with front-back 
polarity signify EMT. Consequently, cells following EMT show increased motile potential (Hay, 
1995; Hugo et al, 2007; Voulgari & Pintzas, 2009). 
Progression of solid tumors involves spatial and temporal occurrences of EMT, whereby 
tumor cells acquire a more invasive phenotype. Subsequently, the disseminated mesenchymal 
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tumor cells must undergo the reverse transition – mesenchymal-epithelial transition (MET) –, 
in order to recapitulate the pathology of the corresponding primary tumor (Hugo et al, 2007). 
This cell plasticity is the key for the success of metastasis, and introduces malignant 
progression as a dynamic process (Hugo et al, 2007). 
 
1.5    Fibronectin and the neoplastic process 
Oncogenic transformation causes a pleiotropic change in cellular properties including 
alterations in adhesion and morphology, loss of cytoskeletal organization, as well as loss of FN. 
The reasons for the loss appear to vary and include reduced synthesis, reduced binding and 
increased rates of degradation (Hynes & Yamada, 1982; Olden & Yamada, 1977). 
FN is the major component of ECM. Its strong susceptibility to proteolytic degradation was 
known since its discovery and was largely used to identify the different binding sites of ECM 
components and others on the molecule. The parallel increase of plasma FN and proteolytic 
enzymes, namely MMPs, as well as the increased levels of FN fragments is observed in tissues 
and biological fluids of cancer patients. In addition, it has been observed that the level of cell-
surface FN is greatly reduced in transformed cells (Akiyama et al, 1995; Furcht et al, 1984; 
Hynes, 1976; Kenny et al, 2008; Warawdekar et al, 2006). Indeed, given the involvement of FN 
in adhesion to ECM, effects on invasion and metastasis might be expected from alterations in 
this aspect of cell function (Hynes & Yamada, 1982). On the other hand, FN fragments may 
show new properties that the native molecule does not exhibit (Kenny et al, 2008). 
 
In studies on the activity of FN in cancer (Labat-Robert, 2002) it was observed, in breast 
cancer patients, lower  levels of pFN in comparison with the levels occurring in healthy 
subjects. In the same study, the presence of FN degradation products in patients where an 
increased proteolytic activity could be anticipated: all investigated patients had high levels of 
FN fragments in the blood plasma; on the contrary, healthy subjects showed the absence of 
such fragments. 
Increased fragmentation of urinary FN was also observed in urine of cancer patients. That 
increase was even more accentuated in patients with distant metastases (Katayama et al, 
1993). 
FN fragmentation appears to be a frequent event in several pathologies: in patients with 
rheumatoid arthritis and osteoarthritis, proinflammatory properties were detected in joint 
tissue and chondrocytes, inducing the activity of MMPs, such as stromelysins, gelatinases and 
collagenases (Homandberg, 2001; Labat-Robert, 2002). 
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Other observations attributed proteolytic activity to some fragments resulting from FN 
proteolysis itself, and also the FN overexpression, thus suggesting the occurrence of a positive 
feedback, which promotes pathological progression, namely in a neoplastic context (Labat-
Robert, 2002; Lopez-Armada et al, 1997). 
Comparing benign breast tumors with adenocarcionomas, it was observed that, besides 
some cFN loss, the pericellular FN fragmentation was a sign of malignancy (Labat-Robert, 2002; 
Labat-Robert et al, 1980). 
Also in breast cancer, cultivation of MCF-7, a human breast adenocarcinoma cell line, in 
serum free medium in the presence of FN upregulated the activity of MMP-2 and MMP-9. By 
blocking α5β1 integrin, the FN-induced MMP activation response was inhibited appreciably, 
which indicates α5β1 mediated signaling events in activation of MMP-2 and MMP-9 (Das et al, 
2008).  
In another study in which the effects of FN on MMP-9 in HEp-2, laryngeal carcinoma cell line, 
were studied, as well as the molecular mechanisms involved, it was also suggested that FN 
induced MMP-9 mainly by involving α5β1 integrin receptor, through the activation of multiple 
signaling pathways (Sen et al, 2010).  
Recent studies (Kenny et al, 2008; Kenny & Lengyel, 2009) have shown the involvement of 
FN fragmentation and vitronectin by MMP-2 in the early stages of the metastatic process of 
the ovarian cancer. Genes encoding several members of MMPs family, including MMP-2 were 
overexpressed in ovarian cancer cells. Based on the importance of these molecules, MMP-2 
inhibition was induced, which resulted in decreased cell proliferation and metastasis in 
experimental mice. 
These results, however, only occurred when the treatment was performed immediately after 
injection of tumor cells; when the inhibitors were administered at a later stage of tumor 
progression, efficacy turned out to be minimal, which coincides with other studies, focused, 
manely, in pancreatic (Bramhall et al, 2001) and gastric cancer (Bramhall et al, 2002; Davies et 
al, 1993). 
The function of MMP-2 proposed in this case is its involvement in promoting adhesive ability 
of ovarian cancer cells through specific cleavage of FN and vitronectin, facilitating and 
foresting the adhesion and invasion of cells by binding to the FN and vitronectin fragments, 
through α5β1 and αvβ3 integrins. 
Also in kidney cancer it was observed a correlation between the FN1 mRNA expression and 
the occurrence of kidney cancer in advanced stage (Waalkes et al, 2010). 
In parallel, other studies attribute anti-tumor properties to some fragments derived from FN. 
Synthetic peptides derived from FN have been used to inhibit metastasis, by interfering with 
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interactions tumor-host and functions as adhesion and motility (anti-adhesion therapy) 
(Humphries et al, 1986; Humphries et al, 1988; Saiki, 1997). Peptides derived from FN, 
including the pentapeptide GRGDS (Gly-Arg-Gly-Asp-Ser), appeared to inhibit lung metastasis 
when administered in mice tumor cells (Humphries et al, 1986; Humphries et al, 1988). Further 
studies used the polymeric peptide poli(RGD), showing also  inhibition of lung and liver 
metastasis in mice with different types of human and murine metastatic cells (Saiki, 1997). 
A polymeric form of FN, “superfibronectin” (sFN) – constructed in vitro, by treating FN with a 
76 amino acids peptide, derived from FIII1, FIII1C (anastellin) – revealed an antimetastatic 
activity when administered systemically to tumors implanted in mice. Also anastellin itself 
reduced the tumor growth in mice, this effect being correlated with a low density of blood 
vessels in mice treated tumors (Yi & Ruoslahti, 2001). 
More recently, a new peptide derived from FN, FNIII14, showed antimetastatic properties by 
inhibiting cell adhesion of lymphoma cells to vascular cell adhesion molecule 1 (VCAM-1) and 
to FN (Kato et al, 2002). 
 
 
ECM represents a critical target of oncogenic transformation. Among its most abundant 
components, FN stands out. Given its special role in terms of functional properties, FN can be 
seen as a potential new tumor marker or even as a target for tumor therapy. 
Metastases formation, as a result of secondary tumor growth, is the main cause of mortality 
in cancer patients. This is particularly relevant in the context of solid tumor growth. For the 
present study, adenocarcinoma of the uterine cervix and colorectal carcinoma are the elected 
models.    
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2. Aims 
This work aims to clarify the role of FN, and its proteolytic fragments, in tumor growth and 
metastases formation, and to determine if the levels of FN expression in solid tumors could be 
used as a prognostic marker of the disease. 
With this intent, an experimental work was performed based on the construction of a 
plasmid containing the FN coding sequence, which was used to transfect human cell lines of 
colorectal adenocarcinoma (HCT15) and uterine cervix adenocarcinoma (HeLa), and in chinese 
hamster ovary cells (CHO). In vivo, we induced orthotopic xenograft tumors in BALB/c-SCID 
mice by using control and transfected cells. 
As specific aims, we sought to evaluate the expression of FN in control and transfected cells, 
the in vitro alterations due to FN expression, particularly on MMPs activity, cell migration and 
angiogenesis, and the role of FN/FN fragments in tumor progression in in vivo models. 
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3. Materials and Methods 
3.1    BIOLOGICAL MATERIAL 
The FN gene was amplified by using RNA from human colon adenocarcinoma cell line SW480 
(ATCC, CCL-228™).  
The plasmid amplification was performed in One-shot TOP 10 Chemically Competent 
Escherichia coli (C4040-10, Invitrogen). 
In vitro assays were developed in human cancer cell lines: colon adenocarcinoma (HCT15) 
and uterine cervix adenocarcinoma (HeLa). Chinese hamster ovary cells (CHO) were used as a 
positive control for FN protein expression. 
The assays in which endothelial cells were used were performed with human umbilical vein 
endothelial cells (HUVEC). 
The in vivo orthotopic models were developed in 6 weeks old BALB/c-SCID mice, males for 
colon cancer model and females for uterine cervix cancer model.  
 
 
3.2    METHODS 
The experimental work was performed according to the following tasks.  
 
3.2.1    Construction of pcDNA3 - full-length fibronectin (pcDNA3-flFN) expression 
vector and stable transfection of HCT15, HeLa and CHO cell lines. 
3.2.1.1    Amplification of FN coding sequence 
Total RNA was obtained from SW480 cells, using an RNeasy RNA extraction kit (74106, 
Qiagen), according to the manufacturer’s protocol.  
Specificity and enrichment of cDNA from FN was ensured by using a panel of 23 reverse 
primers of 15 mer (table 6) in the Reverse Transcription (RT) Reaction.  
Full-length FN (embryonic) was amplified from cDNA using specific primers (table 6) and 
Polymerase Chain Reaction (PCR) was performed with Expand Long Template PCR System 
(11681834001, Roche). 
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3.2.1.1.1    Reverse transcription polymerase chain reaction (RT-PCR) 
The RNA concentration was determined spectrophotometrically by measuring absorbance at 
260 nm in a Nanodrop 2000 (Thermo Scientific). 
Reverse transcription polymerase chain reaction (RT-PCR) is a variant of Polymerase Chain 
Reaction (PCR) – technique used to amplify a specific DNA fragment – which produces DNA 
copies of an RNA template. In RT-PCR an RNA strand is first reverse transcribed into its 
complementary DNA (cDNA), using the enzyme reverse transcriptase, and the resulting cDNA 
is amplified by PCR. 
The cDNA was synthesized from 1 µg of total RNA, to which 0.5 µl of primers mix (10µM, 23 
reverse primers of 15 mer, specific to FN (table 6)) were added, and sterile bidestilled water to 
complete a total volume of 8 µl. The mixture was incubated at 70:C, for 10 minutes, in order to 
occur the annealing between RNA and the reverse primers. Then, at 4:C, the following mixture 
was added, for a final volume of 20 µl: 4 µl of First Strand Buffer 5X (Y00146, Invitrogen), 2 µl 
of 0.1M DTT (dithiothreitol) (Y00147, Invitrogen), 2 µl of 200mM dNTPs (deoxynucleotides), 1 
µl of 40 U/µl RNAse OUT™ (10777-019, Invitrogen), 1 µl of 200 U/µl Superscript II® (18064-022, 
Invitrogen), 0.5 µl of ssDNAp (single strand DNA binding proteins) (M3011, Promega), and 
sterile bidestilled water up to 12 µl. 
The cDNA synthesis was performed in a T3000 thermocycler (Biometra), using the following 
conditions: 
 
                           Table 1 - Program used for the cDNA synthesis. 
Stage Temperature (:C) Time 
First strand cDNA synthesis 
Reverse transcriptase inactivation 
Cooling 
42 
75 
4 
4 hrs 
15 min 
∞ 
 
 
3.2.1.1.2    Expand Long Template PCR 
PCR is a highly sensitive technique used to amplify a DNA sequence of interest. The 
amplification occurs in a thermocycler, where cyclic temperature variations are generated, so 
that DNA can be replicated through enzymatic action. The sequence to be amplified is 
delimited by using a pair of primers – short oligonucleotides, each one complementary to one 
of the strands of the flanking regions -, which initiate DNA synthesis. The remainder elongation 
is ensured by a thermostable DNA polymerase. 
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The reaction proceeds in three steps: heat denaturation of the hydrogen bonds in DNA 
double helix, producing two single strands; annealing of the primers to each strand at the end 
of the sequence to be amplified; and an elongation step during which DNA polymerase enzyme 
attaches strand and continues to synthesize the complementary strand. These three steps 
must be repeated in 30 to 40 cycles to obtain a satisfactory amount of DNA. 
 
FN (full-length) amplification was accomplished using an Expand Long Template PCR System 
(11681834001, Roche), an optimized enzyme blend that contains thermostable Taq DNA 
polymerase and Tgo DNA polymerase, a thermostable DNA polymerase with proofreading 
activity, and specially developed three-buffer system optimized to generate PCR products from 
5 to 20 kb in length (FN is approximately 6.4 kb in length).  
 
The Expand PCR mixture was made for a final volume of 50 µl and contained: 4 µl of cDNA, 5 
µl of Buffer 1 (buffer system used to amplify DNA fragments up to 9 kb in length), 1.5 µl of 
forward primer (table 6), 1.5 µl of reverse primer (table 6), 7 µl of 200mM dNTPs, 0.75 µl of 
Expand mix, and sterile bidestilled water added to complete the final volume. Primers were 
designed as instructed by pcDNA3.1 Directional TOPO Expression kit protocol (K4900-01, 
Invitrogen) (see 3.2.1.2). 
The Expand PCR was performed in a T3000 thermocycler (Biometra), according to the 
program described in the table 2. 
 
Table 2 - Program used for FN Expand PCR. 
Stage  Temperature (:C) Time Cycles t 
Initial denaturation 94 2 min 1  
Denaturation 94 10 s   
Annealing 56 30 s 10  
Elongation 68 10 min   
Denaturation 94 15 s   
Annealing 56 30 s 25 20 s 
Elongation 68 10 min   
Cooling 4 ∞   
 
After PCR, the amplified product was visualized by electrophoresis, in a 1.2% (w/v) agarose 
(in TBE buffer 1X (diluted from TBE buffer 10X, EC-860, National diagnostics)) gel, stained with 
0.05% (v/v) ethidium bromide and under UV (BioDocAnalyse Transilluminator, Biometra). 
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The DNA fragment with the expected size was extracted, using a QIAquick Gel Extraction kit 
(28706, Qiagen), according to the manufacturer’s protocol, and then sequenced. 
 
3.2.1.1.2.1    DNA sequencing  
DNA sequencing is the determination of the order of the nucleotides in a DNA molecule.  
The DNA sequence can be determined by dye-terminator sequencing. In this method, the 
double stranded DNA fragment to be analyzed is mixed with a single primer binding to a strand 
complementary to the strand to be sequenced, DNA polymerase and a nucleotide mixture 
containing ordinary dNTPs and ddNTPs (dideoxynucleotides), nucleotides lacking a 3'-hydroxyl 
(-OH) group at the polymerization site, and labeled with a fluorescent molecule – a different 
fluorochrom specific for each nucleotide. In a reaction based on the same principle as PCR, 
insertion of ddNTP terminates the extension of that particular strand. The insertion of ddNTPs 
is random, but, after a series of cycles, the sequencing reaction contains a mixture of copies of 
one strand ended at each base. Strands are separated by size in a capillary electrophoresis. 
During the electrophoresis, the dyes of strands of equal length are excited passing a laser and 
the specific light emission is detected, generating, this way, the nucleotide sequence of the 
DNA fragment.  
 
DNA sequencing was used to confirm the sequence of the band obtained from Expand PCR. 
For that purpose two sequencing reaction mixtures were made – one contained the forward 
primer and the other one the reverse primer, so that the two strands of the DNA fragment 
could be sequenced – for a final volume of 20 µl for each mixture. Each mixture contained: 3 µl 
of Big dye ™ Terminator v1.1 and 2 µl of Big dye sequencing buffer 5X (BigDye® Terminator 
v3.1 Cycle Sequencing kit, 4337456, Applied Biosystems), 1 µl of forward or reverse primer 
(table 6), 4 µl of DNA template, and sterile bidestilled water up to 20 µl. 
Sequencing reaction was carried out in a T3000 thermocycler (Biometra), according to the 
program described in the table 3. 
Samples were then purified, using an AutoSeq G-50 dye terminator removal kit (27-5340-02, 
GE Healthcare Life Sciences), according to the manufacturer’s instructions. 
The automated sequencing was performed in an ABI Prism™ 310 Genetic Analyzer (Applied 
Biosystems). 
The results were obtained as electroferograms after analysis with Sequencing Analysis 3.4.1 
software. 
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Table 3 - Program used for sequencing reaction. 
Stage Temperature (:C) Time Cycles 
Initial denaturation 96 5 min 1 
Denaturation 96 10 s  
Annealing 56 5 s 25 
Elongation 60 4 min  
Cooling 4 ∞ 1 
 
 
3.2.1.2    Plasmid construction and cloning 
The pcDNA3-flFN construction (appendix B) was used performed by using the pcDNA™3.1 
Directional TOPO Expression kit (K4900-01, Invitrogen), which uses linearized, topoisomerase I-
activated pcDNA™3.1D⁄V5-His-TOPO® for directional cloning of a blunt-end PCR product. 
pcDNA™3.1D/V5-His-TOPO® is a 5.5 kb expression vector designed to facilitate rapid 
directional cloning of blunt-end PCR products for expression in mammalian cells. The plasmid 
contains an ampicillin resistance gene and a geneticin resistance gene, allowing the selection 
of transformants and transfectants, respectively (appendix B). 
Topoisomerase I binds to duplex DNA at specific sites and cleaves the phosphodiester 
backbone after 5′-CCCTT in one strand. The energy from the broken phosphodiester backbone 
is conserved by formation of a covalent bond between the 3′ phosphate of the cleaved strand 
and a tyrosyl residue (Tyr-274) of topoisomerase I. This bond can subsequently be attacked by 
the 5′ hydroxyl of the original cleaved strand, reversing the reaction and releasing 
topoisomerase. TOPO® cloning exploits this reaction to efficiently clone PCR products. 
Directional joining of double-strand DNA using TOPO®-charged oligonucleotides occurs by 
adding a 3′ single-stranded end (overhang) to the incoming DNA. This single-stranded 
overhang is identical to the 5′ end of the TOPO®-charged DNA fragment. 
In this system, PCR products are directionally inserted by adding four bases to the forward 
primer (CACC). The overhang in the cloning vector (GTGG) invades the 5′ end of the PCR 
product, anneals to the added bases and stabilizes the PCR product in the correct orientation.  
 
Plasmid cloning was performed by transforming One-shot TOP 10 Chemically Competent 
Escherichia coli (C4040-10, Invitrogen), according to the manufacturer’s protocol.  
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3.2.1.3    Plasmid isolation 
From each plate (as recommended, two different volumes were plated), 10 colonies were 
picked and cultured in 5 ml of LB medium (appendix A) containing 50 µg/ml ampicillin, at 37:C, 
with shaking, overnight. 
The plasmid isolation from each culture was accomplished by using a Plasmid DNA MiniPreps 
kit (SP-PMN-100, EasySpin), according to the protocol provided by the manufacturer. 
The isolated plasmids were then visualized in a 1.2% (w/v) agarose (in TBE buffer 1X (diluted 
from TBE buffer 10X, EC-860, National diagnostics)) gel, stained with 0.005% ethidium 
bromide, after electrophoresis, under UV transillumination (BioDocAnalyse Transilluminator, 
Biometra). 
The plasmid with the expected size was lastly confirmed as being pcDNA3-flFN through 
digestion with restriction enzymes, and PCR followed by DNA sequencing.  
 
3.2.1.3.1    Restriction endonucleases digestion  
Restriction enzymes (or restriction endonucleases) are enzymes that cleave DNA at specific 
sequences, restriction sites, generating restriction fragments. These enzymes can be used for 
excision of a DNA sequence of interest if the DNA region is flanked by specific restriction 
sites. 
 
By knowing the pcDNA3-flFN restriction sites (NEBcutter analysis 
(tools.neb.com/NEBcutter2/)) and their respective recognizing restriction enzymes, a 
restriction digestion was performed on the plasmid. For this purpose, the enzymes NotI 
(ER0591, Fermentas) and BamHI (R01362, New England BioLabs) were used. 
The digestion reaction took place in a T3000 thermocycler (Biometra), at 37:C, overnight, 
and it was prepared as follows: 2 µl of 10 U/µl NotI or 20 U/µl BamHI, 1 µl of Buffer O 10X 
(B05, Fermentas) or NEBuffer 3 10X (B70035, New England BioLabs), respectively, 4 µl of DNA 
template, and sterile bidestilled water up to 20 µl. 
The products were loaded in a 1.2% (w/v) agarose (in TBE buffer 1X (diluted from TBE buffer 
10X, EC-860, National diagnostics)) gel, stained with 0.005% ethidium bromide, and visualized 
under UV (BioDocAnalyse Transilluminator, Biometra). 
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3.2.1.3.2    PCR  
PCR was a complement technique used for pcDNA3-flFN validation. For that purpose, a 
forward primer that attached to a pcDNA3.1D⁄V5-His-TOPO® sequence, and a reverse primer 
specific to FN fragment were used (table 6).  
Three reaction mixtures were made, only varying in the reverse primer, each one for a final 
volume of 25 µl and containing: 2.5 µl of PCR Rxn Buffer 10X (Y02028, Invitrogen), 2 µl of 
200mM dNTPs, 1 µl of each primer, 1.5 µl of 50 mM MgCl2 (Y02018, Invitrogen), 1 µl of 
template DNA, 0.5 µl of 5U/µl Taq DNA polymerase (18038-026, Invitrogen), and sterile 
bidestilled water up to 25 µl. 
PCR was carried out in a T3000 thermocycler (Biometra), according to the program described 
in the table 4. 
The PCR products were loaded in a 2% (w/v) agarose (in TBE buffer 1X (diluted from TBE 
buffer 10X, EC-860, National diagnostics)) gel, stained with 0.005% ethidium bromide, and 
visualized under UV (BioDocAnalyse Transilluminator, Biometra). The fragment of the expected 
size was extracted using a QIAquick Gel Extraction kit (28704, Qiagen), following the protocol 
provided by the manufacturer, and then sequenced. 
The sequencing followed the procedures explained in 3.2.1.1.2.1. 
 
Table 4 - Program used for PCR. 
Stage Temperature (:C) Time Cycles 
Initial denaturation 95 5 min 1 
Denaturation 94 50 s  
Annealing variable 
1)
 30 s 25 
Elongation 72 50 s  
Final elongation 72 7 min 1 
Cooling 15 ∞  
1)
  46.8 :C and 51.2 :C.    
 
The pcDNA3-flFN concentration was determined spectrophotometrically by measuring 
absorbance at 260 nm in a Nanodrop 2000 (Thermo Scientific). 
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3.2.1.4    Stable transfection of HCT15, HeLa and CHO cell lines 
3.2.1.4.1    Cell culture 
 Cell lines were obtained from American Type Culture Collection (ATCC): HCT15 (CCL-225™), 
HeLa (CCL-2™) and CHO (CCL-61™).  
Cell lines were maintained at 37:C in a humidified 5% CO2 environment in MEM Alpha 
Medium 1X (22561-021, Invitrogen) (HCT15, HeLa and CHO), supplemented with 10% Fetal 
Bovine Serum (FBS) (16000-044, Invitrogen) and 1X Antibiotic-Antimycotic (15240062, Anti-
Anti) (Invitrogen). Cells were grown to 75 - 100% optical confluence before they were 
detached by incubation with 0.05% trypsin-EDTA 1X (25300-054, Invitrogen) for 5 min, at room 
temperature. 
Whenever necessary, the cell number was determined with the help of a Bürker counting 
chamber.  
 
3.2.1.4.2    Transfection 
HCT15, HeLa and CHO were transfected with pCDNA3-flFN, using the cationic liposome 
Lipofectamine™ 2000 (11668019, Invitrogen). For that, each cell line was previously grown, in a 
25 cm2 cell culture flask, to approximately 80% confluence. For each flask, 1 µg of DNA 
(pcDNA3-flFN) was diluted into 500 µl of serum free MEM Alpha Medium 1X (22561021, 
Invitrogen), and 20 µl of Lipofectamine™ 2000 were also diluted into 500 µl of serum free 
MEM Alpha Medium 1X. After incubation for 5 minutes, at room temperature, the two 
dilutions were mixed and incubated, at room temperature, for 20 minutes to allow DNA-
Lipofectamine™ 2000 complexes to form. The complexes were finally added directly to each 
flask, replacing the ordinary culture medium. 
After incubation for 4-6 hours, at 37:C, in a humidified 5% CO2 environment, it was added 
new complete culture medium. 
For each cell line, a control group, not transfected, was maintained in parallel. 
Transfected cells were selected by continuous supplementation of Geneticin (10131027, 
Invitrogen) to the growth medium. Decreasing concentrations were used, with an interval of 
one week, until the last concentration that was maintained: 1 mg/ml, 500 µg/ml, 100 µg/ml, 
50 µg/ml and 10 µg/ml.  
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3.2.2    In vitro assays 
3.2.2.1    Real-time PCR for FN 
Real-time PCR is the technique of collecting data throughout the PCR process as it occurs, 
combining amplification and detection. This is achieved using a variety of different fluorescent 
chemistries that correlate PCR product concentration to fluorescence intensity. Real-time PCR 
can be used to quantify nucleic acids by two methods: absolute quantification and relative 
quantification. Absolute quantification gives the exact number of target DNA molecules by 
comparison with a DNA standard of known concentration, serially diluted. In relative 
quantification, changes in sample gene expression are measured based on internal reference 
genes to determine fold-differences in expression of the target gene. 
 
RNA was extracted from each cell line (control and transfected), using an RNeasy RNA 
extraction mini kit (74104, Qiagen), according to the manufacturer’s protocol. 
cDNA synthesis was performed as described in 3.2.1.1.1, but, this time, 10 µM random 
primers (11043922, Roche) were used (0.5 µl), and the first strand synthesis occurred during 
90 minutes. 
For each sample, a reaction mixture was made, in triplicate, for a final volume of 25 µl, per 
reaction, containing: 12.5 µl of Fast SYBR® Green Master Mix (4385612, Applied Biosystems), 
0.75 of forward primer (table 6), 0.75 of reverse primer (table 6), and sterile bidestilled water 
up to 24 µl. 
FN expression was determined by relative quantification. The housekeeping gene used to 
normalize the samples was 18S. Each PCR experiment included one non-template control well. 
 Real-time PCR was carried out in an ABI Prism® 7900HT Sequence Detection System (Applied 
Biosystems), according to the program described in the table 5. 
 
Tabela 5 - Program used for real-time PCR.  
Stage Temperature (:C) Time Cycles 
Initial denaturation 95 2 min 1 
Denaturation 95 15 s 
45 
Annealing 60 1 min 
Dissociation curve 95 to 60 15 min  
Dissociation curve was performed exclusively for relative quantification. 
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3.2.2.2    Immunoprecipitation 
Immunoprecipitation is used to precipitate a protein out of a solution using an antibody 
specific to that particular protein. This technique was used to immunoprecipitate FN out of the 
media supernatants of the cell lines. 
 
In order to confer a neutral pH – suitable for immunoprecipitation – to supernatants, these 
were subjected to dialysis with pH 7 phosphate buffer, using a dialysis tubing cellulose 
membrane (cut-off 10 kDa) (D9777-100FT, Sigma-Aldrich). The proteins in each sample were 
then quantified and the concentrations equalized among the samples, based on the Bradford 
method, using a Bio-Rad Protein Assay Reagent (161-0156, Bio-Rad), according to the protocol 
provided by the manufacturer. 
Once comparable, each sample (21 ml) was divided to be immunoprecipitated with three 
different antibodies specific to FN – polyclonal anti-human FN (F3648, Sigma-Aldrich), 
monoclonal anti-human FN (F0916, Sigma-Aldrich) and polyclonal anti- human/mouse/rat 
FN1−C-Terminal (SAB4500974, Sigma-Aldrich) –: the sample was first incubated with 4 µl of 
the respective antibody, at 4:C, overnight, under rotatory agitation. Then, it was incubated 
with 50 µl of Protein G Sepharose® (P3296, Sigma-Aldrich), also at 4:C, overnight, under 
rotatory agitation. The Protein G beads with bound antibodies were finally harvested by 
centrifugation at 2500 rpm, for 10 minutes, at 4:C. The complexes were still rinsed twice with 
Dulbecco’s Phosphate Buffered Saline 1X (04-479Q, Cambrex) and centrifuged at 2500 rpm, for 
10 minutes, at 4:C. Forty µl of β-mercaptoethanol:loading buffer 5X (appendix A)  (1:10) were 
added to the sample, which was stored at -20:C. 
In parallel, a human serum sample was also immunoprecipitated with polyclonal anti- 
human/mouse/rat FN1−C-Terminal (SAB4500974, Sigma-Aldrich), to be used as a positive 
control. 
 
3.2.2.3  SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and 
western blotting 
Western blotting is a technique used to detect specific proteins in a given sample. This 
method uses SDS-PAGE to separate, in this case, denatured proteins by the length. The 
proteins are then transferred to a membrane to make the proteins accessible to antibody 
detection. 
This technique was used to detect the FN immunoprecipitated.  
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The complexes immunoprecipitated were boiled at 95-100:C for 10 minutes, to denature the 
protein and separate it from the protein G beads, and centrifuged at 14000 rpm, for 2 minutes, 
to precipitate the beads and keep the protein in the supernatant.  
The samples were then loaded in a 10% polyacrilamide gel (appendix A) and electrophoresis 
was carried out in Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad) at 150V, for 1 hour, 
into TGS buffer 1X (TGS buffer 10X, 161-0772, Bio-Rad). 
After electrophoresis, proteins were transferred to a nitrocellulose membrane (162-0112, 
Bio-Rad), into transfer buffer (appendix A), with a Mini Trans-Blot® Electrophoretic Transfer 
Cell (Bio-Rad), at 35V, overnight, at 4:C.  
Blocking of non-specific binding was achieved by placing the membrane in a 5% (w/v) 
solution of non-fat milk in PBS Tween 20 (appendix A). 
For protein detection, the membrane was incubated with the primary antibody specific to 
FN, diluted 1:1000 in non-fat milk in PBS Tween 20, overnight, at 4:C, with shaking. Primary 
antibodies used were: polyclonal anti-human FN (F3648, Sigma-Aldrich), monoclonal anti-
human FN (F0916, Sigma-Aldrich) and polyclonal anti- human/mouse/rat FN1−C-Terminal 
(SAB4500974, Sigma-Aldrich). After rinsing the membrane, three times, with PBS Tween 20, to 
remove unbound primary antibody, the membrane was exposed to the secondary antibody 
(anti-rabbit (31460, Thermo Scientific) and anti-mouse (31430, Thermo Scientific)), conjugated 
with horseradish peroxidase (HRP) and diluted 1:5000 in non-fat milk in PBS Tween 20. The 
incubation lasted for 2 hours, at room temperature, shaking. After rinsing the membrane, the 
reactivity of HRP was developed by SuperSignal® West Pico Chemiluminescent Substrate 
(34080, Thermo Scientific). Digital images of the western blotting were obtained in a ChemiDoc 
XRS System (Bio-Rad) with Image Lab software. Bands were quantified using Image J software 
(rsb.info.nih.gov/ij/). 
 
3.2.2.4    Immunofluorescence 
Immunofluorescence uses the specificity of antibodies labeled with fluorochromes to target 
specific biomolecules within a cell, allowing their visualization in the sample. In this work, 
immunofluorescence was performed using sequencially two antibodies: a primary antibody, 
that recognizes and binds to the target molecule, and a secondary antibody, which carries the 
fluorophore and recognizes and binds to the primary antibody. 
 
From each cell line (control and transfected), cells were grown on lamellae, previously 
coated in 0.2% (w/v) gelatin, until they reached approximately 80% of confluence. Cells were 
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fixed in 2% (w/v) paraformaldehyde  for 15 minutes at 4:C, blocked with 0.1% (w/v) BSA in PBS 
1X for 45 minutes at room temperature, and incubated with primary antibody overnight 
(diluted in 0,1% (w/v) BSA in PBS 1X, 1:100). Antibodies used were polyclonal anti-human FN 
(F3648, Sigma-Aldrich), monoclonal anti-human FN (F0916, Sigma-Aldrich) and polyclonal anti-
human/mouse/rat FN1−C-Terminal (SAB4500974, Sigma-Aldrich), monoclonal anti-human α3 
(MAB1952Z, Millipore), monoclonal anti-human/mouse/rat β1−C-terminal (EP1041Y, Abcam), 
polyclonal anti-human/mouse β3 (ab47584, Abcam) and monoclonal anti-human/mouse 
tenascin-C (MAB2138, R&D Systems). After rinsing three times, 5 minutes, with PBS 1X, cells 
were incubated with the secondary antibodies for 2 hours, at room temperature. Secondary 
antibodies used (diluted in 0,1% (w/v) BSA in PBS 1X, 1:1000) were: Alexa Fluor® 488 anti-
mouse (A-11001, Invitrogen), Alexa Fluor® 488 anti-rabbit (A-11034, Invitrogen), Alexa Fluor® 
488 anti-rat (A-11006, Invitrogen).The slides were rinsed, once again, three times with PBS 1X, 
prior to be mounted in VECTASHIELD media with DAPI (4'-6-diamidino-2-phenylindole) (H-
1200, Vector Labs). Cells were examined by standard fluorescence microscopy using an Axio 
Imager.Z1 microscope (Zeiss).  
The same procedures described above were performed for negative controls, with the 
expception of the incubation with the primary antibody. 
Images (x200 field) were acquired with AxioVision software and processed with ImageJ 
software.  
 
3.2.2.5    Zymography 
Zymography is an electrophoretic technique, performed with native PAGE, for examining 
MMPs activity in cell extracts and media samples. In this method, proteins are separated, 
according to their hydrodynamic size, in a gel that includes a substrate co-polymerized with 
the gel, for the detection of enzyme activity. 
 
Media supernatants of each control and transfected cell line were concentrated by using 
Amicon® Ultra-4 Centrifugal Filter Units (UFC800308, Millipore). Loading buffer 5X (appendix 
A) was added to each sample and the mixtures were loaded in a 12% polyacrilamide gel 
(appendix A) with 0.1% (w/v) gelatin. Electrophoresis was performed with a Mini-PROTEAN 
Tetra Electrophoresis System (Bio-Rad), at 150V, for 90 minutes, into TGS buffer 1X (TGS buffer 
10X, 161-0772, Bio-Rad). Gel was incubated in renaturating buffer (25% TritonX-100 (v/v)) for 1 
hour, with agitation, after which the gel was incubated, overnight, at 37:C in collagenase 
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buffer (appendix A). Staining was performed with 0.5% (w/v) Coomassie Blue R-250 for 30 
minutes and destaining with destilled water, with agitation.  
The gel was scanned and the bands were quantified using ImageJ software. 
 
3.2.2.6    In vitro wound healing assay  
The in vitro wound healing assay is a method to study directional cell migration in vitro that 
mimics cell migration during wound healing in vivo. 
 
The cells from each line were grown in a 3.8 cm2 tissue culture wells to a confluent 
monolayer. In each well, a scratch was made with a P20 pipette tip to the length of the well. 
After the scratch, the culture medium was replaced to remove detached cells. A timelapse 
experiment was performed and followed under an Olympus CK2 inverted optical microscope 
(Olympus). Phase images (x200 field) were acquired at the following time points: 0, 8, 24 and 
36 hours. 
 
3.2.2.7    In vitro tube formation assay 
Endothelial cells tube formation assay measures the ability of endothelial cells, at 
subconfluent densities, to form capillary-like structures.  
 
For this experiment, HUVEC – obtained from ATCC (CRL-1730™) –, passages 2 to 5, were 
previously cultured and maintained according to the standard procedures (see 3.2.1.4.1), in 
Endothelial Basal Medium-2 (EBM-2) (00190860, Lonza) supplemented with 10% FBS (16000-
044, Invitrogen) and Anti-Anti 1X (15240062, Invitrogen) in 0.2% gelatin coated flasks. 
HUVEC were seeded on 3.8 cm2 Matrigel™ Basement Membrane Matrix (356234, BD 
Biosciences) coated wells, at a density of 1x104 cells per well in supplemented EBM-2. After 
cells adhesion, this culture medium was replaced by: conditioned media from each cell line 
(control and tranfected), 10% FBS (16000-044, Invitrogen) and 1% Anti-Anti (15240062, 
Invitrogen) supplemented MEM Alpha Medium 1X (22561-021, Invitrogen), and 10% FBS 
(16000-044, Invitrogen), 1% Anti-Anti 100X (15240062, Invitrogen) and 0.1% Fibronectin from 
bovine plasma (F1141, Sigma-Aldrich-Aldrich) supplemented MEM Alpha Medium 1X 
(Invitrogen).  
Phase images (x40 field) were acquired in an Olympus CK2 inverted optical microscope 
(Olympus), 24 hours after the medium replacement. 
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3.2.2.8    Real-time PCR for VEGF-121, VEGF-165 and VEGF-189 
VEGF isoforms expression was determined by absolute quantification for each control and 
transfected group within cell line. The expression of each sample was calculated with respect 
to a standard calibration curve that represents a serial dilution of cDNA from HUVEC.  
cDNA synthesis was performed as described in 3.2.2.1. For each sample, a reaction mixture 
was made, in triplicate, for a final volume of 25 µl, per reaction, containing: 12.5 µl of 
TaqMan® Universal PCR Master Mix (2X) (4304437, Applied Biosystems), 15.75 µl of forward 
primer (table 6), 15.75 µl of reverse primer (table 6), 0.83 µl of probe (table 6) and sterile 
bidestilled water up to 25 µl. 
The housekeeping gene used to normalize the samples was 18S (Eukariotic 18S rRNA 
Endogenous Control - 20x, 4319413E, Applied Biosystems). For that, a different reaction 
mixture was made, containing: 12.5 µl of TaqMan® Universal PCR Master Mix (2X) (4304437, 
Applied Biosystems), 1.25 µl of Eukariotic 18S rRNA Endogenous Control (4319413E, Applied 
Biosystems) and sterile bidestilled water up to 25 µl. 
Each PCR experiment included one non-template control well. 
Real-time PCR was carried out in an ABI Prism® 7900HT Sequence Detection System (Applied 
Biosystems), according to the program described in the table 5. 
 
3.2.2.9    Real-time PCR for KDR, FLT1, Angiopoietin-1, Angiopoietin-2, SCF and SDF1 
KDR, FLT1, Angiopoietin-1, Angiopoietin-2, SCF and SDF1 expression was determined by 
relative quantification for each control and transfected group within cell line.  
cDNA synthesis and reaction mixtures for each target were performed as described in 
3.2.2.1. The housekeeping gene used to normalize the samples was 18S. Each PCR experiment 
included one non-template control well. 
Real-time PCR was carried out in an ABI Prism® 7900HT Sequence Detection System (Applied 
Biosystems), according to the program described in the table 5. 
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3.2.3    In vivo assays 2) 
3.2.3.1    Orthotopic xenograft tumors induction  
Tumorigenic capability of control and transfected human cancer cell lines was addressed by 
inducing the formation of orthotopic xenograft tumors in 6 weeks old BLAB/c-SCID mice. 
For establishment of tumor xenografts, cells were rinsed in Dulbecco’s phosphate buffered 
saline (PBS) 1X (04-479Q, Cambrex), harvested by scraping, and ressuspended in PBS at a 
concentration of 2 x 107 cells/ml. Each BALB/c-SCID mice was anestheziated by intraperitoneal 
injection of 100 µl of ketamine/medetonidin anesthesia. 
 
For HCT15, the induction of the formation of xenograft tumors was performed by injection of 
1 x 106 cells, per mouse (n=3 (male) for control HCT15; n=3 (male) for transfected HCT15), in 
the visceral wall of cecum. For HeLa, the formation of xenograft tumors was also induced by 
orthotopic injection of 1 x 106 cells, per mouse (n=3 for control HCT15; n=3 for transfected 
HCT15), in the uterus, by transvaginal inoculation. 
After surgery, animals were awakened by receiving 100 µl of atipamezole reversor. Animals 
also received 100 µl of enrofloxacine antibiotic and enrofloxacine/meloxicam antibiotic/anti-
inflammatory during 3 days. 
 
2) 
All procedures involving live animals were performed by a professional authorized by Direcção Geral de Veterinária. 
 
3.2.3.2    Flow cytometric analysis of endothelial and hematopoietic progenitor cells  
Flow cytometry (FCM) is a technique for the analysis of multiple parameters of individual 
cells within heterogeneous populations. These analyses are performed by passing the cells 
through a laser beam and capturing the light that emerges from each cell as it passes through. 
One of the most common ways to study cell characteristics involves the use of fluorescent 
molecules, such as fluorophore-labeled antibodies. 
 
For the analysis of endothelial and hematopoietic progenitor cells, blood samples were, 
periodically, collected (70 µl) from every animal for FCM acquisition. To each 70 µl of blood, 70 
µl of 0.1% (w/v) BSA in PBS 1X were added. The mixture was incubated for 20 minutes, at 4:C, 
with 1 µl of the following antibodies: APC anti-mouse CD117 (c-Kit) (105812, Biolegend), PE 
anti-mouse Flk-1 (555308, BD Pharmingen) and FITC anti-mouse Ly-6A/E (553335, BD 
Pharmingen). After an incubation of 15 minutes, at room temperature with 1 ml of Red blood 
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cells lysis buffer 1X (diluted from RBC lysis buffer 10X, 420301, Biolegend), the samples were 
centrifuged at 1200 rpm, for 5 minutes. The supernatant was discarded and the pellets were 
rinsed twice with 0.1% (w/v) BSA in PBS 1X. Cells were ressuspended in 200 µl of 0.1% (w/v) 
BSA in PBS 1X. Acquisitions were performed using a FACSCalibur flow cytometer (BD 
Biosciences) with a minimum of 10000 events for each sample, and further analysed using 
CellQuest Pro software.  
 
3.2.3.3    Animals euthanasia  
The animals were maintained for approximately 2 months. After this time, they were 
sacrificed in a carbon dioxide chamber.  
From each mouse, tumors and the main target organs for metastases were collected for 
further histological analysis, as well as the blood for western blotting. 
 
3.2.3.4    Western blotting 
FN in the peripheral blood of animals was detected by western blotting. For that, the serum 
was extracted, after coagulation, and FN immunoprecipitated with polyclonal anti-human FN 
(F3648, Sigma-Aldrich), also used as the primary antibody for western blotting. The secondary 
antibody was anti-rabbit (31460, Thermo Scientific). The procedures involved are described in 
3.2.2.2. 
 
3.2.3.5    Histological analysis 
The collected organs were fixed in 10% formalin and embedded in paraffin (bones were 
decalcified into an EDTA solution (appendix A), for one week, at 4:C, before embedding in 
paraffin). Tissues were serially sectioned (3 µm). After retrieving the antigens in a PT-Link 
device (Dako) – module for tissue specimens for pre-treatment process of deparafinization, 
rehydration and epitope retrieval –, tissues were permanently deparaffinized by incubation, 
for 1 minute, with decreasing concentrations of ethanol (85%, 70% and 50%) and bidestilled 
water. Specimens were then stained with hematoxylin and eosin (H&E). 
After deparafinization, sections were also stained for mast cells detection. For that, tissues 
were stained in toluidine blue solution (appendix A) for 3 minutes; after rinsed in bidestilled 
water, tissues were dehydrated, by incubation, for 1 minute, with increasing concentrations of 
ethanol (50%, 75%, 80%, 90% and 100%) and xylene. The slides were then mounted with 
Entellan® (1079610500, Merck) and examined with a Primo Star optical microscope (Zeiss). 
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Tissues were also used in immunohistochemistry for cytokeratin-19 (CK-19) and cytokeratin-
7 (CK-7), and in immunofluorecence for E-cadherin.   
Immunohistochemistry staining commonly uses a secondary antibody conjugated to a 
peroxidase, an enzyme that catalyses a color-producing reaction. Peroxidase is an enzyme 
found in several tissues, which makes it necessary to block the endogenous peroxidase for a 
specific staining. 
 For immunohistochemistry, after antigen retrieval and tissue dehydration (incubation for 
one minute with decreasing concentrations of ethanol: 50%, 70% and 85%), endogenous 
peroxidase was blocked by incubating the tissues in 3% (v/v) hydrogen peroxide in methanol, 
for 30 minutes.  
The specimens were then deparaffinized, rinsed three times, for 5 minutes, with tris 
buffered saline (TBS) 1X (appendix A), and, finally, incubated with BSA 1% (w/v) in TBS, for 20 
minutes. The tissues were then incubated with the primary antibody, diluted in 0.1 (w/v) BSA 
in TBS 1X, overnight, at 4:C. The primary antibodies used were: monoclonal anti-human 
cytokeratin 19 (1:100) (M0888, Dako) and monoclonal anti-human cytokeratin 7 (1:100) 
(M7018, Dako). 
The further procedures were performed using a Dako EnVision+System-HRP (DAB) (Dako) 
kit for use with mouse (K4006) and rabbit (K4010) antibodies, according to the manufacturer’s 
instructions. 
The same procedures described above were performed for negative controls, with the 
exception of the incubation with the primary antibody. 
For immunofluorescence, after deparaffinization, procedures followed the steps described in 
3.2.2.3. The primary antibodies used were: monoclonal anti-E-cadherin (1:100) (18-0223, 
Sigma-Aldrich). 
The slides were mounted with Entellan® (1079610500, Merck) and examined with a Primo 
Star optical microscope (Zeiss). 
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Table 6 – Primers and probes used during the experimental work. 
Reference Primer (5’3’) Tm (°C) Technique 
FN 
Rev1: AACCGGGCTTGCTT 37.0 RT-PCR 
Rev2: CACACACTCTAACA 33.0 RT-PCR; PCR; Sequencing 
Rev3: GGGCCAGATCCGCT 41.0 RT-PCR 
Rev4: CCCTTCTGTGGTGC 39.0 RT-PCR; PCR; Sequencing 
Rev5: CTCATCATGTGACC 35.0 RT-PCR 
Rev6: GTAGCACTGGTATC 35.0 RT-PCR 
Rev7: GGTGTGCTGGTGCT 39.0 RT-PCR 
Rev8: CTCCCCATCCTCAG 39.0 RT-PCR; PCR; Sequencing 
Rev9: AACTGCTGGTCCCT 37.0 RT-PCR 
Rev10: CCACGGTCAGTCGG 41.0 RT-PCR 
Rev11: TTCTACTCCTGGAG 35.0 RT-PCR 
Rev12: GGGATGATGGTATC 35.0 RT-PCR 
Rev13: GGGGAGGTGCCCAG 43.0 RT-PCR 
Rev14: GAGGCTCGAGGAGC 41.0 RT-PCR 
Rev15: ACTTGCTCCCAGGC 39.0 RT-PCR 
Rev16: TGGATTCTGAGCAT 33.0 RT-PCR 
Rev17: GCAGGAGACCCAGG 41.0 RT-PCR 
Rev18: CTGGAACGGCATGA 37.0 RT-PCR 
Rev19: GTCACCTGAGTGAA 35.0 RT-PCR 
Rev20: TGGTCCGCCTAAAA 35.0 RT-PCR 
Rev21: GTCTTTCAGTGCCT 35.0 RT-PCR 
Rev22: GTTGCCTCATGAGC 37.0 RT-PCR 
Rev23: TTACTCTCGGGAAT 33.0 RT-PCR 
Fw: CACCCCGTCTCAACATGCTTAGG                                    70.5 Expand PCR; Sequencing 
Rev: TTACTCTCGGGAATCTTCTC 57.5 Expand PCR; Sequencing 
Fw: AAGGTTCGGGAAGAGGTTGT 63.7 Real-time PCR (RQ) 
Rev: TGGCACCGAGATATTCCTTC 63.8 Real-time PCR (RQ) 
T7 Fw: TAATACGACTCACTATAGGG 50.9 PCR; Sequencing 
18S 
Fw: GCCCTATCAACTTTCGATGGT 65.1 Real-time PCR (RQ) 
Rev: CCGGAATCGAACCCTGATT 66.0 Real-time PCR (RQ) 
KD 
Fw: GTGACCAACATGGAGTCGTG 64.2 Real-time PCR (RQ) 
Rev: CCAGAGATTCCATGCCACTT 64.0 Real-time PCR (RQ) 
FLT1 
Fw: CACCAAGAGCGACGTGTG 64.5 Real-time PCR (RQ) 
Rev: TTTTGGGTCTCTGTGCCAG 63.9 Real-time PCR (RQ) 
SDF1 
Fw: CAGATGCCCATGCCGATT 67.2 Real-time PCR (RQ) 
Rev: AGTTTGGAGTGTTGAGAATTT 64.9 Real-time PCR (RQ) 
Angiopoietin-1 
Fw: AGGAAATGCTGCAGATGTTGATAA 65.4 Real-time PCR (RQ) 
Rev: GCAGCTCTTCACAGACTGACCA 67.0 Real-time PCR (RQ) 
Angiopoietin-2 
Fw: GGAACACTCCCTCTCGACAA 64.2 Real-time PCR (RQ) 
Rev: ATTCACCGTGGCAGTCACTA 63.2 Real-time PCR (RQ) 
SCF 
Fw: GTAGCAGTAATAGGAAGGCCA 64.1 Real-time PCR (RQ) 
Rev: AGAAAACAATGCTGGCAATGC 66.0 Real-time PCR (RQ) 
  
Reference Primer (5’3’) Probe (6-FAM-5’3’ TAMRA) Tm (°C) Technique 
VEGF-121 
Fw: CCAGCACATAGGAGAGATGAGCTT ACAGCACAACAAATGTGAATGC
AGACCAAA  
66.6 Real-time PCR (AQ) 
Rev: CGGCTTGTCACATTTTTCTTGTC 66.5 Real-time PCR (AQ) 
VEGF-165 
Fw: CCAGCACATAGGAGAGATGAGCTT ACAGCACAACAAATGTGAATGC
AGACCAAA   
66.6 Real-time PCR (AQ) 
Rev: AGGCCCACAGGGATTTTCTT 65.7 Real-time PCR (AQ) 
VEGF-189 
Fw: AATGTGAATGCAGACCAAAGAAAG AGAGCAAGACAAGAAAAAAAAT
CAGTTCGAGGAA 
65.0 Real-time PCR (AQ) 
Rev: AGGGAACGCTCCAGGACTTATA 64.7 Real-time PCR (AQ) 
Tm: melting temperature; 
RQ : relative quantification; 
AQ: absolute quantification.  
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4. Results 
With the intent to study the role of FN in tumor development and progression, an 
experimental work was designed arising from the establishment of two groups within each cell 
line used, differing in the levels of FN produced. That difference was achieved by transfecting a 
group of cells of each cell line with a plasmid containing the human embryonic FN gene (full 
length FN), pcDNA3-flFN. As mentioned above, the cell lines used were HCT15, HeLa and CHO. 
For each cell line, it was also maintained a control group of cells composed of cells not 
transfected. CHO was used as a positive control, due to their lack of a control mechanism of 
transcription.  
During the experimental work, several experiments were developed and the results 
compared between the groups. 
 
4.1    IN VITRO ASSAYS 
4.1.1    Quantification of FN expression by real-time PCR 
To quantify the difference between groups within each cell line in relative expression levels 
of FN after stable transfection with pcDNA3-flFN, a Real-time PCR assay was carried out (figure 
2).  
 
Figure 2 – Real-time-PCR for FN expression. Relative quantification of FN mRNA levels in control and transfected 
HCT15, HeLa and CHO. Error bars represent standard deviation.  
 
Indeed, it was observed an increase of FN mRNA levels in all transfected groups. That 
increase was higher in HCT15 (24.3 fold) and CHO (16.3 fold) cell lines, than in HeLa (2.5 fold).  
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4.1.2    Evaluation of FN expression by western blotting  
Western blotting was performed to verify if the difference in FN mRNA levels observed 
between control and transfected groups was reflected in FN protein levels, and also if there 
were alterations between groups in regard to FN fragmentation.  Once FN is an extracellular 
molecule, the supernatants from the two groups within each cell line were collected and, after 
immunoprecipitation of FN, the protein was detected and quantified by western blotting 
(figures 3, 4 and 5). 
 
CHO: 
Immunoprecipitation with: 
 polyclonal anti-human FN   (AB1) monoclonal anti-human FN   (AB2) 
polyclonal anti- human/mouse/rat 
FN1−C-Terminal   (AB3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection with: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection with:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection with: 
 
 
 
 
 
IMMUNOPRECIPITATION polyclonal anti-human FN   (AB1) monoclonal anti-human FN   (AB2) 
polyclonal anti- human/mouse/rat 
FN1−C-Terminal   (AB3) 
DETECTION AB1 AB2 AB3 AB1 AB2 AB3 AB1 AB2 AB3 
 C FN C FN C FN C FN C FN C FN C FN C FN C FN 
FN 1 1.46 — 1 6.27 — — — 1 1.32 — 1 0.62 
Fragment 3 — — 1 3.87 — — — — — 1 0.77 
Fragment 4 — — 1 10.18 — — — — — — 
Fragment 5 — — 1 2.02 — 1 1.70 — — — 1 0.41 
 
 
 
AB1 AB2 AB3 
Ctl       FN Ctl       FN Ctl        FN Ctl       FN Ctl       FN  Ctl        FN 
AB1 AB2 AB3 
A 
AB1 AB2 AB3 
Ctl       FN Ctl       FN  Ctl        FN 
HCT15 HeLa CHO 
FN 
Fragment 1 
Fragment 2 
Fragment 5 
Fragment 3 
Fragment 4 
AB1 AB2 AB3 Po i i  
control 
B 
Figure 3 – Western blotting of FN immunoprecipitated from CHO media supernatants. (A) Western blotting analysis of 
FN from the supernatants of control (Ctl) and transfected (FN) cells. For each group, FN was immunoprecipitated with 
three different antibodies specific for FN: polyclonal anti-human FN, monoclonal anti-human FN and polyclonal anti-
FN1−C-Terminal. Membranes were detected also with the three antibodies specific for FN. The positive control used is 
FN from human serum of a healthy individual, immunoprecipitated with polyclonal anti-FN1−C-Terminal and detected 
with the same antibody. Fragments denomination was arbitrary. (B) Western blotting quantification for each band 
detected. Bands are compared between control (C) and transfected (FN) groups.  
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Positive 
control Ctl       FN Ctl       FN  Ctl        FN 
HCT15 HeLa CHO 
The results from western blotting for CHO (figure 3) revealed, globally, higher FN levels in 
transfected group than in control, with a greater significance in the immunoprecipitation with 
polyclonal anti-human FN - detection with polyclonal anti-FN1−C-Terminal condition.  An 
exception was observed in the immunoprecipitation with polyclonal anti-FN1−C-Terminal - 
detection with polyclonal anti-FN1−C-Terminal condition, where FN levels were slightly higher 
in control group than in transfected cells. 
In relation to FN fragments detected, for fragment 3 and 5, results differed among 
conditions. However, largest differences were observed in all situations in which fragments 
levels, including fragment 4, were higher in transfected cells than in control. 
 
HCT15: 
Immunoprecipitation with: 
 polyclonal anti-human FN   (AB1) monoclonal anti-human FN   (AB2) 
polyclonal anti- human/mouse/rat 
FN1−C-Terminal   (AB3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection with: 
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Detection with: 
 
 
 
 
 
IMMUNOPRECIPITATION polyclonal anti-human FN   (AB1) monoclonal anti-human FN   (AB2) 
polyclonal anti- human/mouse/rat 
FN1−C-Terminal   (AB3) 
DETECTION AB1 AB2 AB3 AB1 AB2 AB3 AB1 AB2 AB3 
 C FN C FN C FN C FN C FN C FN C FN C FN C FN 
FN — — — — — — 1 173.64 — 1 1.06 
Fragment 1 — — — — — — 1 165.48 — — 
Fragment 5 1 1.24 — 1 3.09 — 1 272.86 — 1 1.18 — 1 0.76 
 
 
 
 
 
 
AB1 AB2 AB3 
Ctl       FN Ctl       FN Ctl        FN Ctl       FN Ctl       FN  Ctl        FN 
AB1 AB2 AB3 
A 
AB1 AB2 AB3 
FN 
Fragment 1 
Fragment 2 
Fragment 5 
Fragment 3 
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P i e 
control 
B 
Figure 4 – Western blotting of FN immunoprecipitated from HCT15 media supernatants. (A) Western blotting analysis 
of FN from the supernatants of control (Ctl) and transfected (FN) cells. For each group, FN was immunoprecipitated 
with three different antibodies specific for FN: polyclonal anti-human FN, monoclonal anti-human FN and polyclonal 
anti-FN1−C-Terminal. Membranes were detected also with the three antibodies specific for FN. The positive control 
used is FN from human serum of a healthy individual, immunoprecipitated with polyclonal anti-FN1−C-Terminal and 
detected with the same antibody. Fragments denomination was arbitrary. (B) Western blotting quantification for each 
band detected. Bands are compared between control (C) and transfected (FN) groups.  
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Western blotting for HCT15 (figure 4) revealed higher FN levels in transfected cells than in 
control, in both conditions that resulted in its detection, although the difference detected in 
immunoprecipitation with polyclonal anti-FN1−C-Terminal - detection with polyclonal anti-
FN1−C-Terminal condition was almost insignificant; the difference observed in 
immunoprecipitation with polyclonal anti-FN1−C-Terminal - detection with polyclonal anti-
human FN condition was, on the contrary, very significant. Te latter condition also detected 
fragment 1, for each a similar difference was observed. 
Fragment 5 levels were, globally, higher in transfected cells, with a major significance in the 
immunoprecipitation with monoclonal anti-human FN - detection with monoclonal anti-human 
FN condition. The contrary was observed in the immunoprecipitation with polyclonal anti-
FN1−C-Terminal - detection with polyclonal anti-FN1−C-Terminal, but with a small difference.  
 
HeLa:  
Immunoprecipitation with: 
 polyclonal anti-human FN   (AB1) monoclonal anti-human FN   (AB2) 
polyclonal anti- human/mouse/rat 
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IMMUNOPRECIPITATION polyclonal anti-human FN   (AB1) monoclonal anti-human FN   (AB2) 
polyclonal anti- human/mouse/rat 
FN1−C-Terminal   (AB3) 
DETECTION AB1 AB2 AB3 AB1 AB2 AB3 AB1 AB2 AB3 
 C FN C FN C FN C FN C FN C FN C FN C FN C FN 
FN 1 1.34 — — —  — — — — 
Fragment 2 — — — — 1 0.72 — — — — 
Fragment 3 1 0.69 — 1 0.88 — 1 0.19 — — — 1 0.27 
 
 
 
 
 
 
 
The results from western blotting for HeLa (figure 5) showed a modest difference between 
the two groups of cells, with higher FN levels in transfected cells in comparison to control 
group. For the fragments detected, fragments 2 and 3, lower levels were observed in the 
transfected group, also with small differences. 
 
For every cell line, FN fragments were detected that were not observed in the positive 
control. 
 
4.1.3    Expression of FN, integrins and tenascin-C by immunofluorescence 
FN, α3, β1 and β3 integrins, and tenascin-C were detected by immunofluorescence for CHO, 
HCT15 and HeLa cells. Protein expression was compared between control and transfected 
cells. 
 
 
 
 
 
 
 
 
B 
Figure 5 – Western blotting of FN immunoprecipitated from HeLa media supernatants. (A) Western blotting analysis 
of FN from the supernatants of control (Ctl) and transfected (FN) cells. For each group, FN was immunoprecipitated 
with three different antibodies specific for FN: polyclonal anti-human FN, monoclonal anti-human FN and polyclonal 
anti-FN1−C-Terminal. Membranes were detected also with the three antibodies specific for FN. The positive control 
used is FN from human serum of a healthy individual, immunoprecipitated with polyclonal anti-FN1−C-Terminal and 
detected with the same antibody. Fragments denomination was arbitrary. (B) Western blotting quantification for each 
band detected. Bands are compared between control (C) and transfected (FN) groups.  
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Figure 6 – Immunofluorescence 
for FN, α3, β1 and β3 integrins 
and tenascin-C in CHO. 
Comparison between control 
and transfected cells. 
Fluorescence microscopy 
(original magnification: 200x). 
Nuclei were stained with DAPI 
(blue). Scale bar: 100 µm. 
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For CHO (figure 6), a clear difference was observed between control and transfected cells, 
showing higher protein levels in transfected cells than in control. FN detection with 
monoclonal and polyclonal anti-human FN revealed a very tenuous protein expression in 
control cells, mainly with monoclonal antibody. 
For β3 integrin, expressive higher levels were also found in transfected cells. Tenascin-C 
detection revealed increased levels in transfected cells, but in a less expressive manner.  
No evident differences were verified for the other targets.  
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HCT15: 
  
Control Transfected 
α3 integrin 
FN (monoclonal anti-human FN) 
FN (polyclonal anti-human FN) 
 
FN (polyclonal anti-FN1−C-Terminal) 
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In HCT15 (figure7), for transfected cells, higher FN levels were observed, as well as for α3 
and β3 integrins. No significant differences were detected for the remaining targets.  
Tenascin-C  
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β1 integrin 
Figure 7 – Immunofluorescence 
for FN, α3, β1 and β3 integrins, 
and tenascin-C in HCT15. 
Comparison between control 
and transfected cells. 
Fluorescence microscopy 
(original magnification: 200x). 
Nuclei were stained with DAPI 
(blue). Scale bar: 100 µm. 
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HeLa: 
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Figure 8 – Immunofluorescence 
for FN, α3, β1 and β3 integrins 
and tenascin-C in HeLa. 
Comparison between control 
and transfected cells. 
Fluorescence microscopy 
(original magnification: 200x). 
Nuclei were stained with DAPI 
(blue). Scale bar: 100 µm. 
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Immunofluorescence for HeLa (figure 8) showed increased FN levels in transfected cells in 
comparison to control cells, although with a slight significance. For β1 integrin, the same 
difference was observed, also with a moderate expression. 
For the remaining targets, no differences were detected between groups. 
 
4.1.4   Evaluation of MMPs activity by zymography 
Zymography was used to verify if FN is able to interfere in MMPs production/secretion or 
activity in the cell lines used. For that purpose MMPs activity was compared between groups 
within each cell line, by zymography (figure 9). 
 
 
 
 
 
 
 
 
 
 CHO HCT15 HeLa 
 Ctl FN Ctl FN Ctl FN 
MMP-9  1 1.15 1 1.63 1 0.83 
MMP-2  1 0.67 1 2.23 1 0.72 
 
 
  
 
The zymogram obtained (figure 9) revealed enzymatic activity of MMP-9 and MMP-2. 
In CHO cell line, MMP-9 activity was much higher than MMP-2, in both control and 
transfected cells.  
For MMP-9, it was observed a higher activity in control group. The contrary was detected for 
MMP-2. 
Figure 9 – Zymography of CHO, HCT15 and HeLa media supernatants. (A) Zymogram for control and 
transfected groups of each cell line. (B) Quantification of each band detected. Bands are compared between 
control and transfected groups. 
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In HCT15, a higher enzymatic activity was verified for MMP-2, in both groups. 
For both MMPs, a higher activity was found in transfected cell group. 
In HeLa cells, a higher activity was also detected for MMP-2, in both control and transfected 
cells. 
In this cell line, for MMP-9 and MMP-2, a small difference showed a higher enzymatic 
activity observed in control cell group. 
 
4.1.5    Evaluation of cell migration by wound healing assay  
 In vitro wound healing assay was performed to investigate a possible role of FN on the 
migration rate of cells, by comparing control and transfected cell groups (figure 10). The 
evolution of the experiment was monitorized at the following time points: 0, 8, 24 and 30 
hours. 
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Figure 10 – Wound healing assay. Comparison between control and transfected cells for CHO (A), HCT15 (B) and HeLa (C), 
at 0, 8, 24 and 30 hours. Phase microscopy (original magnification: 200x). 
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During the assay, it was observed, in CHO and HCT15 cell lines, a higher cell migration rate in 
pcDNA3-flFN transfected groups compared to control groups. In HeLa, no differences were 
observed between the two groups. 
 
4.1.6    Angiogenesis assays: tube formation assay, real-time PCR for VEGF-121, VEGF-
165 and VEGF-189, KDR, FLT-1, Angiopoietin-1 and Angiopoietin-2 
Tube formation assay and quantification of the expression of VEGF isoforms (VEGF-121, 
VEGF-165 and VEGF-189) and its receptors KDR and FLT-1, Angiopoietin-1 and Angiopoietin-2 
were carried out to study the potential involvement of FN in angiogenesis. 
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Tube formation assay with conditioned medium from CHO revealed a lower number of 
branch points formed by HUVEC in transfected cells (figure 11). 
 
 
 
 
Figure 11 – Tube formation assay with conditioned 
medium from CHO cell line. (A) Representative images 
of Matrigel™-induced HUVEC tube formation in 
monoculture maintained in conditioned medium from 
control and transfected CHO. Phase microscopy (original 
magnification: 40x) (B) Average number of branch points 
in 5 high power fields. Error bars represent standard 
deviation. 0 
5 
10 
15 
20 
25 
30 
CHO Ctl CHO FN 
A
ve
ra
ge
 n
u
m
b
er
 o
f 
b
ra
n
ch
  
p
o
in
ts
 
B 
A 
70 
 
0 
1 
2 
3 
VEGF-121 VEGF-165 VEGF-189 
A
Q
  (
ar
b
it
ra
ry
 u
n
it
s)
 HCT15 C 
HCT15 FN 
HCT15 
Control Transfected 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
For HCT15, as in CHO, a lower number of branch points was verified in the tube formation 
assay with conditioned medium from transfecetd cells (figure 12). In relation to the expression 
levels of VEGF isoforms (figure 13), absolute quantification showed, in control cells, similar 
levels of VEGF-121, VEGF-165 and VEGF-189. Transfected cells, on the other hand, differed 
from control group, exhibiting an increased VEGF-121 expression and lower levels of the other 
isoforms.  
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Figure 12 – Tube formation assay with conditioned 
medium from HCT15 cell line. (A) Representative images 
of Matrigel™-induced HUVEC tube formation in 
monoculture maintained in conditioned medium from 
control and transfected HCT15. Phase microscopy 
(original magnification: 40x) (B) Average number of 
branch points in 5 high power fields. Error bars represent 
standard deviation. 
Figure 13 – Real-time-PCR for VEGF isoforms 
expression in HCT15. Absolute quantification 
of VEGF-121, VEGF-165 and VEGF-189 mRNA 
levels in control and transfected HCT15. Error 
bars represent standard deviation.  
 
Figure 14 – Real-time-PCR for KDR, FLT-1, Angiopoietin-1 
(ANGIOP1) and Angiopoetin-2 (ANGIOP2) in HCT15. Relative 
quantification for mRNA levels in control and transfected 
HCT15. Error bars represent standard deviation.  
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For the same cell line, relative quantification (figure 14) revealed a decrease in VEGF 
receptors KDR and FLT-1 expression, more evident in KDR, in transfected cells, and higher 
expression levels of angiopoietin-2. 
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For HeLa, tube formation assay (figure 15) resulted in a tenuous difference in the number of 
branch points formed, showing a small increase when conditioned medium from transfected 
cells was used. Absolute quantification of VEGF isoforms (figure 16) showed, as in HCT15, 
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Figure 15 – Tube formation assay with conditioned 
medium from HeLa cell line. (A) Representative images 
of Matrigel™-induced HUVEC tube formation in 
monoculture maintained in conditioned medium from 
control and transfected HeLa. Phase microscopy (original 
magnification: 40x) (B) Average number of branch points 
in 5 high power fields. Error bars represent standard 
deviation. 
Figure 16 – Real-time-PCR for VEGF isoforms 
expression in HeLa. Absolute quantification 
of VEGF-121, VEGF-165 and VEGF-189 mRNA 
levels in control and transfected HeLa. Error 
bars represent standard deviation.  
 
Figure 17 – Real-time-PCR for KDR, FLT-1, Angiopoietin-1 
(ANGIOP1) and Angiopoietin-2 (ANGIOP2) in HeLa. Relative 
quantification of mRNA levels in control and transfected 
HeLa. Error bars represent standard deviation.  
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similar expression levels of VEGF isoforms in control cells, and, in transfected cells, in 
comparison to that group, an increased expression of VEGF-121 and lower expression levels of 
the other isoforms. 
By relative quantification (figure 17), a decreased expression of KDR and angiopoietin-1 and 
2 were detected in transfected cells. 
 
Alfa-MEM medium Alfa-MEM medium + FN (1:1000) 
 
 
 
 
 
 
 
 
 
 
 
 
Control experiment for tube formation assay using alfa-MEM medium resulted in a decrease 
of the number of branch points formed when FN was added to the medium (figure 18). 
 
4.1.7   Quantification of SCF and SDF-1 expression by real-time PCR  
Expression of SCF (stem cell factor, c-Kit-ligand) and SDF-1 (stromal cell-derived factor-1) was 
addressed by real-time PCR. Relative quantification showed a decrease in the expression of 
both cytokines, at mRNA levels, in transfected cells, for both HCT15 and HeLa cell lines (figures 
19 and 20). 
 
 
Figure 18 – Tube formation assay control experiment 
with supplemented Alfa-MEM medium and Alfa-MEM 
medium + FN (1:1000). (A) Representative images of 
Matrigel™-induced HUVEC tube formation in 
monoculture maintained in supplemented Alfa-MEM 
medium and Alfa-MEM medium + FN (1:1000). Phase 
microscopy (original magnification: 40x) (B) Average 
number of branch points in 5 high power fields. Error 
bars represent standard deviation. 
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4.2    IN VIVO ASSAYS 
4.2.1   Flow cytometric analysis of endothelial and hematopoietic progenitor cells 
Analysis of endothelial and hematopoietic progenitor cells showed, for the animals 
inoculated with HCT15, an increase of endothelial progenitor cells (EPCs) (Sca+,Flk+ cells) since 
the inoculation (figure 21), both for the animals inoculated with control and transfected cells. 
That increase was more pronounced in the latter group. The same trend was found for 
hematopoietic progenitor cells (HPCs) (cKit+ cells) until the last time point (56 days), when the 
percentage of cKit+ cells was higher in the control group (figure 22). 
In the animals inoculated with HeLa, it was not observed any trend in any of the groups, for 
EPCs (figure 23). For HPCs (figure 24), there was a decrease in the number of cKit+ cells, during 
the experiment, for the animals inoculated with control HeLa, and an increase for the animals 
inoculated with transfected HeLa. 
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Figure 19 – Real-time-PCR for SCF and SDF-1 in 
HCT15. Relative quantification of mRNA levels 
in control and transfected cells. Error bars 
represent standard deviation.  
 
Figure 20 – Real-time-PCR for SCF and SDF-1 in 
HeLa. Relative quantification of mRNA levels in 
control and transfected cells. Error bars 
represent standard deviation.  
 
Figure 21 – Flow cytometric analysis of endothelial 
progenitor cells (Sca+,Flk+ cells) for mice inoculated 
with HCT15. Comparison of percentage of Sca+,Flk+ 
cells between control (C) and transfected subgroups 
(FN), at 0, 20 and 56 days. Error bars represent 
standard deviation.  
 
Figure 22 – Flow cytometric analysis of hematopoietic 
progenitor cells (cKit+) for mice inoculated with 
HCT15. Comparison of percentage of cKit+ cells 
between control (C) and transfected (FN) subgroups, at 
0, 20 and 56 days. Error bars represent standard 
deviation.  
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4.2.2   Evaluation of FN expression in the serum of animal models by western 
blotting 
A western blotting was carried out to quantify FN and its proteolytic fragments in the serum 
of the xenograft orthotopic BALB/c-SCID (figure 25). 
 
 
 
 
 
 
 
    
 
 
 
 
 
For both animal groups, FN levels were almost equivalent between mice inoculated with 
control and transfected cells. Fragments were detected only for the animals inoculated with 
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Figure 23 – Flow cytometric analysis of endothelial 
progenitor cells (Sca+,Flk+ cells) for mice inoculated 
with HeLa. Comparison of percentage of Sca+,Flk+ cells 
between control (C) and transfected (FN) subgroups, at 
0, 13 and 40 days. Error bars represent standard 
deviation.  
 
Figure 24 – Flow cytometric analysis of hematopoietic 
progenitor cells (cKit+) for mice inoculated with HeLa. 
Comparison of percentage of cKit+ cells between 
control (C) and transfected (FN) subgroups, at 0, 13 
and 40 days. Error bars represent standard deviation.  
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Figure  25 – Western blotting of FN immunoprecipitated from the serum of xenograft orthotopic BALB/c-SCID. 
(A) Reresentative western blotting analysis of FN from the serum of mice inoculated with control (Ctl) and 
transfected (FN) cells (HCT15 and HeLa). For each group, FN was immunoprecipitated with polyclonal anti-
human FN. Membranes were detected with the same antibody. The positive control used is FN from human 
serum of a healthy individual, immunoprecipitated with polyclonal anti-FN1−C-Terminal and detected with the 
same antibody. Fragments denomination was arbitrary. (B) Western blotting quantification. Bands are compared 
between the two groups. 
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HeLa, in which higher levels were observed, especially for fragment 5, in the subgroup 
inoculated with transfected cells. 
 
4.2.3   Histological analysis 
Macroscopic observation showed that both groups of orthotopic mice developed tumor in 
the point of inoculation. A larger tumor mass was observed in the mice inoculated with the 
transfected cells, for both cell lines (figures 26 and 27). 
Histological analysis consisted of tumor cells detection, by CK-19 and CK-7 staining for HCT15 
and HeLa cells, respectively, E-cadherin and mast cells detection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.1.1   Tumor cells detection in xenograft tumors 
For mice inoculated with HCT15, histological analysis of the collected organs showed the 
presence of metastases in the liver of both subgroups (figure 29A). Lung metastases were also 
found but only for the control mice (figure 29B). Tumor analysis revealed a more invasive 
activity of cancer cells in control mice (figure 29C).  
 
 
Figure 26 – Macroscopic observation of 
xenograft orthotopic BALB/c-SCID 
inoculated with HCT15. (A) 
Representative image of the animals 
inoculated with control HCT15. (B) 
Representative image of the animals 
inoculated with transfected HCT15. 
 
A B 
* 
* 
tumor 
tumor 
Figure 27 – Macroscopic observation of 
xenograft orthotopic BALB/c-SCID 
inoculated with HeLa. (A) 
Representative image of the animals 
inoculated with control HeLa. (B) 
Representative image of the animals 
inoculated with transfected HeLa. 
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HCT15:  
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Figure 28 – Immunoreactivity for cytokeratin-19 (CK-19) in xenograft orthotopic BALB/c-SCID inoculated with 
control (Ctl) and transfected (FN) HCT15. Representative images of liver (A), lung (B) and tumor (C). Light 
microscopy (original magnifications: 40x and 100x). CK-19 stained in brown and nuclei in blue. 
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HeLa: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
  
For mice inoculated with HeLa, lung metastases were found in the control mice (figure 29A).  
Histological analysis of primary tumors showed no differences between mice inoculated with 
control and transfected HeLa (figure 29B). 
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Figure 29 – Immunoreactivity for cytokeratin-7 (CK-7) and H&E (Hematoxylin and Eosin) in xenograft orthotopic 
BALB/c-SCID inoculated with control and transfected HeLa. Representative images of lung (A) and primary tumor 
(B). Light microscopy (original magnifications: 40x and 100x). CK-7 stained in brown and nuclei in blue.  
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4.2.3.2   Detection of E-chaderin in xenograft tumors 
E-cadherin staining, performed on xenograft tumors, revealed no differences between mice 
inoculated with control and transfected HCT15 (figure 30A) and HeLa (figure 30B). In HeLa, 
only the normal tissue stains for E-cadherin.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 30 – Immunofluorescence for E-cadherin in the primary tumor of xenograft orthotopic BALB/c-SCID. 
Representative images for HCT15 (A) and HeLa (B) groups. Fluorescence microscopy (original magnification: 
200x). Nuclei were stained with DAPI (blue). Scale bar: 100 µm. 
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4.2.3.3   Detection of mast cells in xenograft tumors 
Mast cells detection revealed, for HCT15, a higher mast cells infiltration in tumor (figure 
31A). For HeLa, no mast cells were detected (figure 31B).  
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Figure 31 – Toluidine blue staining for mast cells in the primary tumor of xenograft orthotopic BALB/c-SCID. 
Representative images for HCT15 (A) and HeLa (B) groups. Light microscopy (original magnification: 100x). Mast 
cells are stained in violet (arrows). Scale bar: 50 µm. 
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5. Discussion         
ECM represents a critical intervenient of oncogenic transformation. Cancer steps are 
significantly dependent on the permissive nature of the microenvironment and ECM 
proteolysis assumes great importance in this context (Chambers & Matrisian, 1997; Polette et 
al, 2004; Werb, 1997). FN is one of the most abundant components of ECM and several studies 
have related FN levels to tumor progression in cancer patients, observing an increase of both 
FN and FN fragments levels (Katayama et al, 1993; Kenny et al, 2008; Kenny & Lengyel, 2009; 
Labat-Robert, 2002; Labat-Robert et al, 1980; Warawdekar et al, 2006). 
Based on this data, it was elected as global objective of this thesis to study the role of FN in 
tumor development and progression. For that purpose, as already described, for tumor cell 
lines HCT15 and HeLa, two groups were created, differing on the FN amounts produced, by 
transfection of a plasmid containing the FN gene (pcDNA3-flFN). CHO cell line, used as a 
positive control, was subjected to the same in vitro experiment. 
 
In a first approach, the FN mRNA levels quantified for each group (figure 2) confirmed the 
expected result after transfection: it was observed an obvious difference between the control 
and the transfected cells, especially in HCT15 and CHO cell lines. The elevated FN mRNA 
expression in transfected CHO – and since this cell line was used as a positive control due to its 
lack of a control mechanism of transcription – proved the success of the transfection. These 
results allowed the progression of the experiment. 
To verify if the difference observed in mRNA was reflected in FN protein levels, western 
blotting and immunofluorescence analysis were carried out. Both techniques confirmed the 
expected difference between groups within each cell line, showing higher protein levels in 
transfected cells in comparison to control groups. In western blotting and real-time PCR, that 
difference was smaller in HeLa than in HCT15 and CHO, which was consistent with real-time 
PCR. 
The results from western blotting (figures 3, 4 and 5) showed, for HCT15 and HeLa, the 
presence of FN fragments that were not observed in the positive control, an 
immunoprecipitated blood sample from a healthy individual. This fact corroborates the results 
from several studies, in which an increase of proteolytic fragmentation of FN was observed in 
cancer patients (Katayama et al, 1993; Kenny et al, 2008; Kenny & Lengyel, 2009; Labat-Robert, 
2002; Labat-Robert et al, 1980; Warawdekar et al, 2006). 
For CHO, FN fragments were also observed. Although CHO are not cancer cells, this is an 
altered cell line with great MMPs secreting activity, which could explain the pattern obtained. 
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The differences among conditions for the same cell line could be explained by the 
specificities of each antibody. Immunoprecipitation with polyclonal anti-FN1−C-Terminal 
revealed the smallest differences between groups. In fact, this is technically considered the 
less specific antibody once it is polyclonal and reacts with three species. Hence, a particular 
focus must be attributed to the results obtained from the other immunoprecipitations.  
For CHO and HCT15, higher levels of FN fragments were obtained in transfected groups, 
which were expected due to the higher amounts of FN expressed.  
 For HeLa, the opposite was observed, but in a very discrete manner. In fact, for this cell line, 
the difference between groups regarding to FN amount was not very evident. 
Immunofluorescence results (figures 6, 7 and 8) were consistent with the prior findings for 
FN expression. The results obtained for FN detection in CHO were consistent with the 
expectation for each antibody and additionally confirmed the success of the transfection.  
For every cell line, the increase of FN in transfected cells was accompanied by an increase of 
integrins expression, which was reasonable once these are the FN receptors. The fact that this 
variation reached different integrins among cell lines may be explained by the different cell 
contexts. 
Tenascin-C is an ECM molecule related to cell adhesion and detachment that interacts with 
FN (Chung et al, 1995), and is implicated in tumorigenesis (Orend & Chiquet-Ehrismann, 2006). 
Immunofluorescence showed tenascin-C expression in the cell lines tested, mainly in HCT15 
and, even in a greater extent, HeLa. In fact, studies have implicated this glycoprotein as being 
highly expressed in the microenvironment of many solid tumors (Orend & Chiquet-Ehrismann, 
2006), including colorectal carcinoma (Emoto et al, 2001; Sis et al, 2004) and uterine cervix 
cancer (Buyukbayram & Arslan, 2002). In CHO, it was observed an increased tenascinC 
expression in transfected cells, although with a very slight significance. For tumor cell lines 
HCT15 and HeLa, however, no difference was verified between groups. 
MMPs activity was analyzed by zymography (figure 9). For every group, MMP-9 and MMP-2 
enzymatic activities were detected. Besides the evidence that MMPs activity is strongly 
associated with tumorigenesis (Kessenbrock et al, 2010), MMP-9 and MMP-2 are thought to be 
the most important MMPs in metastasis (Coussens et al, 2002; Klein et al, 2004; Malemud, 
2006; Serpa et al, 2010; Stetler-Stevenson, 1999). 
For MMP-9, in transfected groups from both CHO and HCT15, results showed an increased 
enzymatic activity, although with more significance in HCT15. For MMP-2, that pattern is 
maintained in HCT15; in CHO, it was observed a decreased activity in transfected cells in 
comparison to control group. These increases in MMPs activity may be directly related to 
higher amounts of FN in media supernatants of transfected cells, which is cleaved by MMPs, 
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and/or FN may induce signaling pathways that culminate in an increased MMPs activity. MMPs 
upregulation, particularly MMP-9 and MMP-2, in fact, has been described for several 
neoplastic contexts (Duffy et al, 2000; Kenny & Lengyel, 2009; Klein et al, 2004), and some 
studies have related FN to MMPs upregulation as an inducer of multiple signaling pathways 
(Das et al, 2008; Han et al, 2006; Mitra et al, 2006; Sen et al, 2010). 
For HeLa, results demonstrated a lower activity of both MMPs in transfected group, although 
the difference obtained has been very small. In fact, and considering the assays mentioned 
above, the difference in FN between control and transfected HeLa was not very accentuated, 
which can explain the results observed. 
The results observed for MMPs activity are also consistent with the pattern obtained for FN 
fragments in western blotting. 
In the study of cell migration, addressed by wound healing assay (figure 10), no differences 
were detected between HeLa groups, whereas in CHO and HCT15 a more accelerated 
directional cell migration was detected. The pattern observed is, once again, consistent with 
the prior results.  
ECM proteolysis is one of the most important events required for cells migration (Hugo et al, 
2007; Voulgari & Pintzas, 2009). MMPs play an important role in this context by cleaving 
several macromolecules of the ECM, facilitating tumor cells migration (Hay, 1995; Hugo et al, 
2007; Voulgari & Pintzas, 2009). The results observed in wound healing assay may, therefore, 
be a consequence of those obtained from zymography. 
The role of FN in tumor angiogenesis was addressed by tube formation assay and 
quantification of the expression of VEGF-121, VEGF-165 and VEGF-189, VEGF receptors KDR 
and FLT1, and angiogenesis promoting growth factors Angiopoietin-1 and Angiopoietin-2. 
VEGF is one of the main inducers of endothelial cell proliferation, differentiation and 
permeability of blood vessels, regulating, therefore, angiogenesis and vasculogenesis (Witsch 
et al, 2010; Zwick et al, 2001). Alternative splicing of VEGF mRNA generates four different 
isoforms, VEGF-121, VEGF-165, VEGF-189 or VEGF-206. VEGF-121 is freely diffusible, whereas 
VEGF-189 is found tightly bound to ECM. VEGF-165 exhibits intermediate properties (Lee et al, 
2005; Park et al, 1993). 
Several studies have provided evidence for the role of VEGF signaling in tumor 
vascularization and metastasis (Padro et al, 2002; Trojan et al, 2004; Zwick et al, 2001). 
Tube formation assay showed for CHO (figure 11) and HCT15 (figure 12) a decrease in the 
number of branch points formed by HUVEC. These observations, for HCT15, were 
accompanied by an increase of VEGF-121 expression and a decrease for VEGF-165 and VEGF-
189 (figure 13). In fact, VEGF-121 is not recognized as a bioactive isoform; the contrary is 
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observed for VEGF-165 and, even with greater evidence, VEGF-189 (Park et al, 1993). This 
evidence together with the lower expression levels of VEGF receptors (figure 14) can explain 
the previous observation in HUVEC.  
For HeLa, the opposite was observed in tube formation assay (figure 15), but with a small 
significance. However, the same differences in VEGF isoforms expression (figure 16) were 
observed between control and transfected cells, as well as in KDR and angiopoietins (figure 
17). 
The control experiment showed, as in HCT15 and CHO, a decrease in the number of branch 
points formed when medium contained FN (figure 18). 
These findings seem to correlate FN levels with a reduced angiogenic activity, contradicting 
some studies in which the opposite was suggested (Nicosia et al, 1993; Viji et al, 2008). A 
similar association was, however, verified in vivo, in breast cancer patients, for which an 
inverse relation between stromal FN and angiogenesis was observed (Takei et al, 1998). Other 
studies have introduced some fragments derived from FN as inhibitors of angiogenesis (Saiki et 
al, 1990; Yi & Ruoslahti, 2001). 
 
Overall, the prior results appear to correlate FN levels with more aggressiveness in the 
neoplastic context, in vitro, suggesting a particular involvement in the migration of cancer 
cells. 
 
In vivo, results obtained from western blotting (figure 25) differed from the ones observed 
for western blotting in vitro for cells media supernatants. Those results should, however, be 
considered with prudence, once the analysis was performed on the animals serum. In addition, 
due to limited volume of serum, only one antibody was used, which could have implied the 
loss of information. 
In vivo, macroscopically, larger tumors were observed for mice inoculated with transfected 
cells, for both cell lines (figures 26 and 27). This observation, and considering the further 
results, relates tumor size to the progression of disease, associating smaller tumors to a more 
advanced tumorigenic process.  In fact, the acquirement of an invasive ability is not directly 
dependent on the number of cells composing the tumor, but on its heterogeneity that favors 
the interaction with the local microenvironment, allowing, ultimately, the dissemination of the 
disease (Scheel et al, 2007; Voulgari & Pintzas, 2009) 
Histological analysis of the xenograft tumors and the organs collected revealed, for the mice 
inoculated with HCT15 cells (figure 28), the presence of metastases in the liver of both 
subgroups, and in the lungs of control mice. Besides, for the latter animals, cancer cells in the 
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xenograft tumors appeared more invasive than in tumors of mice inoculated with transfected 
cells.  
For mice inoculated with HeLa, control subgroup also differed from the subgroup inoculated 
with transfected cells, showing lung metastases that were not observed in the latter subgroup 
(figure 29). 
E-cadherin is a cell-cell adhesion protein. Loss of E-cadherin function or expression has been 
implicated in cancer progression and metastasis, being one of the core elements of EMT (Hugo 
et al, 2007; Klymkowsky, 2005; Voulgari & Pintzas, 2009). E-chaderin detection on primary 
tumors showed no differences within subgroups for both cell lines (figure 30). This result 
appears not to attribute a relevant role of E-cadherin in the previous differences described 
within subgroups, for both cell lines. 
BM-derived endothelial progenitor cells (EPCs) assume an important role in tumorigenesis by 
providing an alternative source of endothelial cells that contribute to neovessel formation, 
namely through paracrine secretion of proangiogenic growth factors as well as by direct 
luminal incorporation into sprouting nascent vessels (Lyden et al, 2001; Witsch et al, 2010). In 
fact, for mice inoculated with HCT15, after tumors formation induction it was observed a 
gradual increase of EPCs for both subgroups (figure 21). That increase was though more 
accentuated in mice inoculated with transfected cells. Indeed, as mentioned above, tumors 
from the latter subgroup were larger than in control. For HeLa, however, and despite the same 
difference regarding tumor mass size has been observed, no significant differences in EPCs 
were detected during the experiment (figure 23). 
BM-derived mast cells have been implicated in tumor growth and invasion and associated 
with poor prognosis (Gao & Mittal, 2009; Strouch et al, 2010), being an abundant source of 
angiogenic factors and MMP-9 (Theoharides & Conti, 2004). Toluidin blue staining in xenograft 
tumors showed, for mice inoculated with HCT15, an enhanced mast cells infiltration in control 
subgroup (figure 31). This observation is, thus, consistent with the observations from tumor 
cells detection.  
SCF is a cytokine that binds to cKit receptor (CD117) in mast cells, promoting their survival, 
proliferation and migration (Broudy, 1997). SDF-1 is a chemokine associated to tumor growth 
and angiogenesis, metastasis and recruitment of BM-derived cells (Kryczek et al, 2007). By 
quantifying, in vitro, the expression of these cytokines, lower levels were observed in 
transfected cells, for both cell lines (figures 19 and 20). Such results also support the previous 
observations. In addition, for mice inoculated with HCT15, lower levels of cKit+ cells were 
measured in the subgroup inoculated with transfected cells (figure 22), which is also according 
to the prior findings. For mice inoculated with HeLa, however, the same relation between SCF 
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and cKit was not observed (figure 24). In fact, cKit is also expressed in other cell types besides 
mast cells, including hematopoetic stem cells (Ronnstrand, 2004). 
 
Results in vivo show, therefore, the occurrence of a more advanced tumorigenic process in 
the mice inoculated with control cells. However, in vitro, for HCT15, the results pointed to a 
greater aggressiveness of transfected cells, in the neoplastic context, based on the increased 
MMPs 9 and 2 activities that, in turn, were suggested to be related to the higher migration rate 
in wound healing assay also observed. In fact, despite representing a requirement for invasion, 
tumor cells with higher migration rates are not necessarily more invasive, since invasion is the 
result of the combination of several factors. One the other hand, in vitro conditions are very 
different form in vivo context, which includes a set of variables that are not present in vitro. A 
tumor exists within a tissue that is constituted by several cell types interacting continuously, 
and, by themselves, they can limit or enhance tumor progression; these conditions cannot be 
introduced in a culture dish. This evidence also allows the introduction of a new data: one of 
the more expressive findings in vitro, for HCT15, was the increased levels of fragment 5 in 
transfected cells, compared to control group. Indeed, several studies have demonstrated 
protective roles of fragments derived from FN (Humphries et al, 1986; Humphries et al, 1988; 
Kato et al, 2002; Saiki, 1997; Yi & Ruoslahti, 2001). Given these observations and the results 
obtained, this fragment arises as a possible explanation for the outcome of the experiment, for 
HCT15. 
Nevertheless, it is important to refer the occurrence of technical fragilities concerning the 
number of animals used that revealed insufficient for such an experiment in vivo, so any final 
conclusion should be taken after validation of the in vivo model. 
For HeLa, in vitro results revealed, collectively, very discrete differences between control and 
transfected cells. Adding to this outcome the same technical barriers verified for HCT15, the 
validation of the in vivo model also emerges as a priority.  
 
5.1    Future perspectives 
Considering the results obtained and the technical fragilities observed, the validation of the 
in vivo model represents the main concern. Nonetheless, it would be important to clarify the 
role of fragment 5 as an eventual therapeutic agent. For that, the sequencing of the fragment 
seems an important future task for further research that could include the reproduction of the 
present experiments.  
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6. Conclusions 
The central aim of this thesis was the study of the role of FN in tumor development and 
progression. For that purpose several experiments were accomplished in vitro, on a first 
approach, and, subsequently, in vivo. 
In vitro, after validation of the success of cells transfection by real-time PCR, western blotting 
and immunofluorescence, our findings suggested an association between increased FN levels 
and higher FN proteolysis.  Besides, higher FN levels were also associated with increased 
MMPs 9 and 2 proteolytic activities, suggesting a direct involvement of FN, once this ECM 
glycoprotein is cleaved by MMPs, and/or its indirect participation by inducing specific signaling 
pathways that culminate in an increased expression or activation of MMPs.  
The prior results also appeared to be related to the observed higher directional migration 
rates for cell groups exhibiting increased FN amounts. 
In vitro findings, which suggested a correlation between FN levels and a more aggressive 
behavior by cancer cells, particularly towards migration, were not, however, confirmed in vivo, 
where a less advanced tumorigenic process was observed in mice inoculated with transfected 
cells. Indeed, a higher migration rate, although essential for tumor progression, does not 
necessarily imply a greater invasive activity, the main responsible for cancer dissemination. On 
the other hand, in vitro conditions do not include many variables existing in vivo.  
These outcomes also prompted us to consider another data observed in vitro for HCT15, in 
which expressive elevated levels of fragment 5 were observed in the medium supernatant 
from transfected cells. Considering some literature that points out the protective roles of some 
fragments derived from FN, this finding may represent a possible explanation for the outcomes 
obtained. 
As future work, nonetheless, we suggest the validation of the in vivo models to confirm the 
results, once some technical fragilities concerning the number of animals used were faced. The 
sequencing of fragment 5 could still be relevant for further investigation. 
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Appendix A 
 
Solutions prepared for the experimental work: 
 
EDTA decalcifying solution 
For 1L: 
 
100 g EDTA (ethylenediaminetetraacetic acid disodium dihydrate); 
100 ml formaldehyde; 
destilled water up to 1 L. 
 
pH 7 
 
PBS Tween 20 
For 1L: 
 
1 ml Tween 20; 
PBS 1X up to 1 L. 
 
  
TBS 10X 
For 1L: 
 
8 g sodium chloride; 
0.63 g Tris; 
4.4 ml hydrochloric acid (1M); 
destilled water up to 1 L. 
 
pH 7.4-7.6 
 
  
Toluidine blue solution 
Toluidine blue stock solution 
 
For 100 ml: 
 
1 g toluidine blue; 
100 ml 70% (v/v) ethanol. 
 
pH 7.4-7.6 
Toluidine blue working dilution 
 
For 50 ml: 
 
5 ml toluidine blue stock solution; 
45 ml 1% (w/v) sodium chloride (pH 2.3). 
 
  
Zymography solutions 
Running gel (10% polyacrilamide gel with gelatin) 
 
For 10 ml: 
 
3.33 ml 30% (w/v) acrylamide 
2.5 ml 1.5 M Tris, pH 8.8 
3 ml destilled water 
1 ml 1.2% (w/v) gelatin 
50 µl 20% (/w/v) SDS (sodium dodecyl sulfate) 
33.3 µl 10% (w/v) APS (ammonium persulfate) 
Stacking gel 
 
For 3 ml: 
 
500 µl 30% acrylamide 
380 µl 1.0 M Tris, pH 6.8 
2.1 ml destilled water 
30 µl 10% (w/v) SDS (sodium dodecyl sulfate) 
30 µl 10% (w/v) APS (ammonium persulfate) 
3 µl TEMED (Tetramethylethylenediamine) 
100 
 
6.7 µl TEMED (Tetramethylethylenediamine) 
Low salt collagenase buffer 10 X  
For 1L: 
 
60.6 g Tris base 
117 g sodium chloride 
5.5 g calcium chloride 
Destilled water up to 1 L 
 
pH 7.6 
Collagenase buffer 1X  
For 1L: 
 
100 ml stock solution 
900 ml destilled water 
670 µl 30% (w/v)  Brij 
Destain solution 
 
For 1L: 
 
100 ml glacial acetic acid 
300 ml methanol 
600 ml destilled water 
Coomassie brilliant blue stock solution 
 
For 500 ml: 
 
250 ml methanol 
0.25 g Coommassie brilliant blue 
200 ml destilled water 
50 ml acetic acid 
Coomassie working dilution 
 
For 500 ml: 
 
150 ml coomassie brilliant blue stock solution 
350 ml destain solution 
  
LB medium  
Loading buffer (Bromophenol blue) 
PBS 10X 
Polyacrilamide gel (10%) 
Transfer buffer 
(Sambrook & Russel, 2001) 
 
 
 
 
 
 
 
 
 
Reference: 
Sambrook J, Russel DW (2001) Molecular cloning: a laboratory manual, 3rd edn. New York: Cold Spring 
Harbor Laboratory Press.  
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Appendix B 
 
 
  
Figure 32 – Map of pcDNA3-flFN. Adapted from “pcDNA™3.1 Directional TOPO® Expression Kit” handbook. 
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